Runway Growth Finance Corp. - Quarter Report: 2023 March (Form 10-Q)

10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


(Mark One)
☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 814-01180

Runway Growth Finance Corp.

(Exact name of registrant as specified in its charter)


Maryland	47-5049745
(State of incorporation)	(I.R.S. Employer Identification No.)


205 N. Michigan Ave., Suite 4200
Chicago, IL	60601
(Address of principal executive offices)	(Zip Code)

(312) 281‑6270

(Registrant’s telephone number, including area code)

Securities Registered Pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share 7.50% Notes due 2027	RWAY RWAYL	Nasdaq Global Select Market LLC Nasdaq Global Select Market LLC
8.00% Notes due 2027	RWAYZ	Nasdaq Global Select Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. Refer to the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b‑2 of the Exchange Act.


Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☒	Smaller reporting company ☐

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b‑2 of the Exchange Act). Yes ☐ No ☒

The issuer had 40,509,269 shares of common stock, $0.01 par value per share, outstanding as of May 9, 2023.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

FORM 10‑Q FOR THE QUARTER ENDED March 31, 2023

Table of Contents


	INDEX	PAGE NO.

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements	1

	Statements of Assets and Liabilities as of March 31, 2023 (unaudited) and December 31, 2022	1

	Statements of Operations for the three months ended March 31, 2023 and 2022 (unaudited)	2

	Statements of Changes in Net Assets for the three months ended March 31, 2023 and 2022 (unaudited)	3

	Statements of Cash Flows for the three months ended March 31, 2023 and 2022 (unaudited)	4

	Schedule of Investments as of March 31, 2023 (unaudited)	5

	Schedule of Investments as of December 31, 2022	15

	Notes to Financial Statements (unaudited)	24

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	50

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	67

Item 4.	Controls and Procedures	68

PART II.	OTHER INFORMATION	69

Item 1.	Legal Proceedings	69

Item 1A.	Risk Factors	69

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	69

Item 3.	Defaults Upon Senior Securities	69

Item 4.	Mine Safety Disclosures	70

Item 5.	Other Information	70

Item 6.	Exhibits	71

SIGNATURES		72

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

RUNWAY GROWTH FINANCE CORP.

Statements of Assets and Liabilities

(In thousands, except share and per share data)


	March 31, 2023			December 31, 2022
	(Unaudited)
Assets
Investments at fair value:
Non-control/non-affiliate investments at fair value (cost of $1,080,015 and $1,126,879, respectively)	$	1,066,654		$	1,114,935
Affiliate investments at fair value (cost of $55,528 and $4,551, respectively)		47,075			2,084
Control investments at fair value (cost of $19,172 and $19,172, respectively)		11,613			9,290
Investment in U.S. Treasury Bills at fair value (cost of $34,978 and $0, respectively)		34,974			—
Total investments at fair value (cost of $1,189,693 and $1,150,602, respectively)		1,160,316			1,126,309
Cash and cash equivalents		3,271			5,761
Interest and fees receivable		9,212			8,766
Other assets		654			930
Total assets		1,173,453			1,141,766
Liabilities
Debt:
Credit facility		372,000			337,000
2026 Notes		70,000			70,000
2027 Notes		152,250			152,250
Unamortized deferred debt costs		(10,327	)		(10,293	)
Total debt, less unamortized deferred debt costs		583,923			548,957
Incentive fees payable		9,572			8,808
Interest payable		8,341			6,221
Accrued expenses and other liabilities		1,810			1,728
Total liabilities		603,646			565,714
Commitments and contingencies (Note 3)
Net assets
Common stock, par value		414			414
Additional paid-in capital		605,774			605,774
Distributable (losses)		(25,565	)		(19,320	)
Treasury stock		(10,816	)		(10,816	)
Total net assets	$	569,807		$	576,052

Shares of common stock outstanding ($0.01 par value, 100,000,000 shares authorized)		40,509,269			40,509,269
Net asset value per share	$	14.07		$	14.22

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Statements of Operations

(Unaudited)

(In thousands, except share and per share data)


	Three Months Ended March 31,
	2023			2022
Investment income
From non-control/non-affiliate investments:
Interest income	$	34,853		$	16,536
Payment in-kind interest income		3,796			1,006
Dividend income		324			385
Fee income		45			391
From affiliate investments:
Interest income		292			—
Payment in-kind interest income		—			90
From control investments:
Interest income		—			494
Payment in-kind interest income		—			330
Total investment income		39,310			19,232
Operating expenses
Management fees		3,959			2,560
Incentive fees		4,563			1,344
Interest and other debt financing expenses		10,920			1,579
Professional fees		533			394
Overhead allocation expense		345			237
Insurance expense		268			269
Administration fee		162			169
Directors' fees		84			89
Tax expense		50			—
Other expenses		180			132
Total operating expenses		21,064			6,773
Net investment income		18,246			12,459
Realized and unrealized gain (loss) on investments
Net realized gain (loss) on non control/non-affiliate investments, including U.S. Treasury Bills		(1,178	)		(371	)
Net realized gain (loss) on investments		(1,178	)		(371	)
Net change in unrealized appreciation (depreciation) on non-control/non-affiliate investments, including U.S. Treasury Bills		(1,421	)		(4,154	)
Net change in unrealized appreciation (depreciation) on affiliate investments		(5,986	)		(3,166	)
Net change in unrealized appreciation (depreciation) on control investments		2,323			(1,915	)
Net change in unrealized appreciation (depreciation) on investments and U.S. Treasury Bills		(5,084	)		(9,235	)
Net realized and unrealized gain (loss) on investments		(6,262	)		(9,606	)
Net increase in net assets resulting from operations	$	11,984		$	2,853
Net increase in net assets resulting from operations per common share	$	0.30		$	0.07
Net investment income per common share	$	0.45		$	0.30
Weighted average shares outstanding		40,509,269			41,375,187

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Statements of Changes in Net Assets

(Unaudited)

(In thousands, except share and per share data)


	Common Stock
	Shares (1)		Amount		Treasury Stock			Paid-in Capital in Excess of Par Value		Accumulated Undistributed Earnings (Losses)			Total Net Assets
Balances at December 31, 2022		40,509,269	$	414	$	(10,816	)	$	605,774	$	(19,320	)	$	576,052
Net increase in net assets resulting from operations		—		—		—			—		11,984			11,984
Issuance of common stock		—		—		—			—		—			—
Reinvestment of dividends		—		—		—			—		—			—
Acquisition of treasury shares		—		—		—			—		—			—
Refunds (payments) of offering costs		—		—		—			—		—			—
Dividends paid to stockholders		—		—		—			—		(18,229	)		(18,229	)
Balances at March 31, 2023		40,509,269	$	414	$	(10,816	)	$	605,774	$	(25,565	)	$	569,807


(1)	Number of shares is shown net of treasury stock repurchases.


	Common Stock
	Shares (1)			Amount		Treasury Stock			Paid-in Capital in Excess of Par Value		Accumulated Undistributed Earnings (Losses)			Total Net Assets
Balances at December 31, 2021		41,380,614		$	414	$	—		$	606,048	$	(267	)	$	606,195
Net increase in net assets resulting from operations		—			—		—			—		2,853			2,853
Issuance of common stock		—			—		—			—		—			—
Reinvestment of dividends		—			—		—			—		—			—
Acquisition of treasury shares		(31,782	)		—		(409	)		—		—			(409	)
Refunds (payments) of offering costs		—			—		—			—		—			—
Dividends paid to stockholders		—			—		—			—		(11,173	)		(11,173	)
Balances at March 31, 2022		41,348,832		$	414	$	(409	)	$	606,048	$	(8,587	)	$	597,466


(1)	Number of shares is shown net of treasury stock repurchases.

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Statements of Cash Flows

(Unaudited)

(In thousands)


	Three Months Ended March 31,
	2023			2022
Cash flows from operating activities
Net increase in net assets resulting from operations	$	11,984		$	2,853
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Purchases of investments		(12,871	)		(85,520	)
Purchases of U.S. Treasury Bills		(34,974	)		—
Payment in-kind interest		(3,755	)		(1,337	)
Sales or repayments of investments		14,199			10,302
Sales or maturities of U.S. Treasury Bills		—			45,000
Net realized (gain) loss on investments, including U.S. Treasury Bills		1,178			371
Net change in unrealized (appreciation) depreciation on investments, including U.S. Treasury Bills		5,084			9,235
Amortization of fixed income premiums or accretion of discounts		(2,868	)		(2,825	)
Amortization of deferred debt costs		701			152
Changes in operating assets and liabilities:
(Increase) decrease in interest and fees receivable		(446	)		(636	)
(Increase) decrease in other assets		276			472
Increase (decrease) in deferred revenue		—			3,185
Increase (decrease) in incentive fees payable		764			(1,150	)
Increase (decrease) in interest payable		2,120			675
Increase (decrease) in accrued expenses and other liabilities		82			(88	)
Net cash used in operating activities		(18,526	)		(19,311	)
Cash flows from financing activities
Payments of deferred debt costs		(735	)		(519	)
Borrowings under credit facility		55,000			86,000
Repayments under credit facility		(20,000	)		(61,000	)
Proceeds from 2026 Notes		—			50,000
Repayments of reverse repurchase agreements		—			(44,775	)
Acquisition of treasury shares		—			(409	)
Dividends paid to stockholders		(18,229	)		(11,173	)
Net cash provided by financing activities		16,036			18,124
Net increase (decrease) in cash		(2,490	)		(1,187	)
Cash and cash equivalents at beginning of period		5,761			4,697
Cash and cash equivalents at end of period	$	3,271		$	3,510
Supplemental and non-cash financing cash flow information:
Taxes paid	$	—		$	—
Interest paid		7,927			199
Non-cash portfolio purchases		—			725

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments (Unaudited)

March 31, 2023

(In thousands, except share and per share data)


Portfolio Company			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares		Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Senior Secured Term Loans
		Application Software
		Circadence Corporation	SOFR+9.50% PIK, 12.26% floor, 7.50% ETP	12/20/2018	12/15/2023		20,655		21,996		17,701	(4)(8)
		Dtex Systems, Inc.	SOFR+9.25%, 9.75% floor, 1.75% ETP	6/1/2021	6/1/2025		10,000		10,051		10,051	(8)
		FiscalNote, Inc.	PRIME+5.00%, 9.00% floor, 1.00% PIK, 4.25% ETP	10/19/2020	7/15/2027		39,249		38,847		38,847	(4)(8)
			PRIME+5.00%, 9.00% floor, 1.00% PIK, 4.25% ETP	9/30/2021	7/15/2027		8,722		8,703		8,703	(4)(8)
			PRIME+5.00%, 9.00% floor, 1.00% PIK, 4.25% ETP	3/28/2022	7/15/2027		17,444		17,235		17,235	(4)(8)
		VTX Intermediate Holdings, Inc. (dba VertexOne)	SOFR+9.00%, 9.50% floor, 4.50% ETP	12/28/2021	12/28/2026		75,000		75,208		74,582	(8)
			SOFR+9.00%, 9.50% floor, 4.50% ETP	5/31/2022	12/28/2026		10,000		9,992		9,944	(8)
		Total Application Software - 31.07%*							182,032		177,063

		Biotechnology
		Mustang Bio, Inc.	SOFR+8.75%, 9.25% floor, 3.50% ETP	3/4/2022	4/15/2027		30,000		29,798		29,798	(8)
		Total Biotechnology - 5.23%*							29,798		29,798

		Data Processing & Outsourced Services
		Interactions Corporation	SOFR+9.26%, 9.76% floor, 3.4375% ETP	6/24/2022	6/15/2027		40,000		39,603		39,603	(8)
		ShareThis, Inc.	SOFR+9.25%, 11.86% floor, 3.00% ETP	12/3/2018	7/15/2025		19,009		19,482		19,190	(8)
			SOFR+9.25%, 11.86% floor, 3.00% ETP	1/7/2019	7/15/2025		741		759		748	(8)
			SOFR+9.25%, 11.86% floor, 3.00% ETP	7/24/2019	7/15/2025		988		1,011		997	(8)
			SOFR+8.25%, 10.86% floor, 3.00% ETP	8/18/2020	7/15/2025		988		1,014		997	(8)
		Vesta Payment Solutions, Inc.	SOFR+7.00%, 9.00% floor, 3.00% ETP	11/29/2022	11/15/2026		25,000		24,581		24,581	(8)
		Total Data Processing & Outsourced Services - 15.11%*							86,450		86,116

		Education Services
		Turning Tech Intermediate, Inc. (dba Echo 360, Inc.)	SOFR+8.50%, 9.00% floor, 13.00% cash cap, 3.00% ETP	6/22/2021	12/14/2025		20,020		20,343		20,343	(4)(8)
			SOFR+8.50%, 9.00% floor, 13.00% cash cap, 3.00% ETP	3/28/2022	12/14/2025		5,005		5,055		5,055	(4)(8)
		Total Education Services - 4.46%*							25,398		25,398

		Electronic Equipment & Instruments
		Brivo, Inc.	SOFR+6.85%, 10.89% floor, 50% of interest PIK, 3.00% ETP	10/20/2022	10/20/2027		45,018		44,642		44,642	(4)(8)
			SOFR+6.85%, 10.89% floor, 50% of interest PIK, 3.00% ETP	2/23/2023	10/20/2027		4,013		3,976		3,976	(4)(8)
		Intellisite Holdings, Inc. (dba Epic IO Technologies, Inc.)	SOFR+9.75%, 10.25% floor, 2.00% ETP	12/17/2021	12/17/2025		19,000		18,850		18,850
			SOFR+9.75%, 10.25% floor, 2.00% ETP	2/28/2022	12/17/2025		3,000		2,997		2,997
			SOFR+9.75%, 10.25% floor, 2.00% ETP	3/29/2022	12/17/2025		5,000		4,984		4,984
			SOFR+9.75%, 10.25% floor, 2.00% ETP	7/19/2022	12/17/2025		3,000		2,985		2,985
			SOFR+9.75%, 10.25% floor, 2.00% ETP	11/16/2022	12/17/2025		2,000		1,966		1,966
			SOFR+9.75%, 10.25% floor, 2.00% ETP	12/27/2022	12/17/2025		2,000		1,967		1,967
			SOFR+9.75%, 10.25% floor, 2.00% ETP	1/31/2023	12/17/2025		2,000		1,960		1,960
			SOFR+9.75%, 10.25% floor, 2.00% ETP	3/13/2023	12/17/2025		2,000		1,957		1,957
		Total Electronic Equipment & Instruments - 15.14%*							86,284		86,284

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments (Unaudited) – (continued)

March 31, 2023

(In thousands, except share and per share data)


Portfolio Company			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares		Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Senior Secured Term Loans
		Health Care Equipment
		Moximed, Inc.	PRIME+5.25%, 8.75% floor, 3.50% ETP	6/24/2022	7/1/2027		15,000		14,807		14,807	(8)
		Revelle Aesthetics, Inc.	PRIME+5.50%, 8.75% floor, 4.00% ETP	3/30/2022	4/1/2027		12,500		12,408		12,408	(8)
		Total Health Care Equipment - 4.78%*							27,215		27,215

		Health Care Technology
		Allurion Technologies, Inc.	PRIME+6.44%, 9.50% floor, 3.00% ETP	12/30/2021	12/30/2026		5,000		4,928		5,147	(8)
			PRIME+6.44%, 9.50% floor, 3.00% ETP	12/30/2021	12/30/2026		20,000		20,169		20,587	(8)
			PRIME+6.44%, 9.50% floor, 3.00% ETP	6/14/2022	12/30/2026		15,000		14,879		15,440	(8)
			PRIME+6.44%, 9.50% floor, 3.00% ETP	10/27/2022	12/30/2026		15,000		14,829		15,440	(8)
		EBR Systems, Inc.	PRIME+4.90%, 8.90% floor, 4.50% ETP	6/30/2022	6/15/2027		20,000		19,700		19,700	(8)
		Mingle Healthcare Solutions, Inc.	SOFR+9.50% PIK, 12.01% floor, 0.25% PIK, 10.50% ETP	8/15/2018	12/15/2023		4,164		4,773		3,996	(4)(8)
		Nalu Medical, Inc.	PRIME+2.70%, 6.70% floor, 2.00% PIK, 4.50% ETP	10/12/2022	10/12/2027		20,172		19,913		19,913	(4)(8)
		Route 92 Medical, Inc.	SOFR+8.48%, 8.98% floor, 3.95% ETP	8/17/2021	7/1/2026		13,436		13,304		13,304	(8)
		SetPoint Medical Corporation	SOFR+5.75%, 9.00% floor, 4.00% ETP	12/29/2022	12/1/2027		25,000		24,856		24,856	(8)
		VERO Biotech LLC	SOFR+9.05%, 9.55% floor, 3.00% ETP	12/29/2020	12/1/2024		25,000		25,231		25,231	(8)
			SOFR+9.05%, 9.55% floor, 3.00% ETP	3/30/2021	12/1/2024		15,000		15,227		15,227	(8)
		Total Health Care Technology - 31.39%*							177,809		178,841

		Human Resource & Employment Services
		CloudPay, Inc.	PRIME+6.25%, 10.25% floor, 2.00% ETP	9/26/2022	8/17/2027		60,000		59,760		59,760	(3)(8)(12)
		Snagajob.com, Inc.	SOFR+8.50%, 9.00% floor, 9.00% cash cap, 2.75% ETP	9/29/2021	9/1/2025		38,024		38,084		37,086	(4)(8)
		Total Human Resource & Employment Services - 17.00%*							97,844		96,846

		Internet & Direct Marketing Retail
		Madison Reed, Inc.	PRIME+4.75%, 11.00% floor, 3.00% ETP	12/16/2022	12/16/2026		9,600		9,383		9,383	(8)
		Marley Spoon AG	SOFR+8.50%, 1.25% PIK, 9.26% floor	6/30/2021	6/15/2025		26,754		26,571		26,571	(3)(4)(8)(11)
			SOFR+8.50%, 1.25% PIK, 9.26% floor	12/29/2021	6/15/2025		8,191		8,156		8,156	(3)(4)(8)(11)
			SOFR+8.50%, 1.25% PIK, 9.26% floor	6/14/2022	6/15/2025		11,763		11,763		11,763	(3)(4)(8)(11)
		Total Internet & Direct Marketing Retail - 9.80%*							55,873		55,873

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments (Unaudited) – (continued)

March 31, 2023

(In thousands, except share and per share data)


Portfolio Company			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares		Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Senior Secured Term Loans
		Internet Software and Services
		Bombora, Inc.	SOFR+5.00%, 5.76% floor, 3.75% PIK, 2.00% ETP	3/31/2021	3/31/2025		21,542		21,587		21,587	(4)(8)
		Fidelis Cybersecurity, Inc.	SOFR+11.00%, 12.00% floor, 2.39% ETP	5/13/2021	5/13/2024		10,051		10,251		9,869	(8)
			SOFR+11.00%, 12.00% floor, 2.39% ETP	3/25/2022	5/13/2024		7,368		7,452		7,235	(8)
		INRIX, Inc.	SOFR+9.00%, 9.76% floor, 2.50% ETP	11/15/2021	11/15/2025		40,000		40,376		40,376	(8)
			SOFR+9.00%, 9.76% floor, 2.50% ETP	5/3/2022	11/15/2025		5,000		5,044		5,044	(8)
		Skillshare, Inc.	SOFR+6.50%, 10.72% floor, 3.00% ETP	11/8/2022	11/8/2026		25,000		24,509		24,509	(8)
		Synack, Inc.	PRIME+4.25%, 8.25% floor	6/30/2022	6/30/2027		35,000		34,914		34,914	(8)
			PRIME+4.25%, 8.25% floor	3/13/2023	6/30/2027		1,520		1,518		1,518	(8)
		Total Internet Software and Services - 25.46%*							145,651		145,052

		Property & Casualty Insurance
		Kin Insurance, Inc.	PRIME+6.25%, 12.50% floor, 3.00% ETP	9/26/2022	9/15/2026		50,000		49,309		49,309	(8)
		Total Property & Casualty Insurance - 8.65%*							49,309		49,309

		System Software
		3PL Central LLC (dba Extensiv)	SOFR+4.50%, 6.50 floor, 2.50% PIK, 2.00% ETP	11/9/2022	11/9/2027		65,571		64,940		64,940	(4)(8)
			SOFR+4.50%, 6.50 floor, 2.50% PIK, 2.00% ETP	3/13/2023	11/9/2027		3,000		3,001		3,001	(4)(8)
		Total System Software - 11.92%*							67,941		67,941

	Total Senior Secured Term Loans - 180.01%*								1,031,604		1,025,736

	Second Lien Term Loans
		System Software
		Dejero Labs Inc.	SOFR+5.00%, 5.50 floor, 5.00% PIK, 3.00% ETP	12/22/2021	12/22/2025		13,833		13,853		13,707	(3)(4)(8)(10)
		Total System Software - 2.41%*							13,853		13,707

	Total Second Lien Term Loans - 2.41%*								13,853		13,707

	Preferred Stocks
		Application Software
		Aria Systems, Inc.	Series G	7/10/2018	N/A		289,419		250		278	(7)
		Total Application Software - 0.05%*							250		278

		Health Care Technology
		CareCloud, Inc.	11% Series A Cumulative Redeemable Perpetual Preferred Stock	1/8/2020	N/A		462,064		12,132		12,785	(15)(17)
		Total Health Care Technology - 2.24%*							12,132		12,785

	Total Preferred Stocks - 2.29%*								12,382		13,063

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments (Unaudited) – (continued)

March 31, 2023

(In thousands, except share and per share data)


Portfolio Company			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares			Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Common Stocks
		Application Software
		FiscalNote, Inc.		10/19/2020	N/A			230,881		438		515	(7)(19)
		Total Application Software - 0.09%*								438		515

		Technology Hardware, Storage & Peripherals
		Quantum Corporation		8/13/2021	N/A			459,720		2,607		529	(3)(7)(15)(17)
		zSpace, Inc.		12/31/2020	N/A			6,078,499		1,119		—	(7)
		Total Technology Hardware, Storage & Peripherals - 0.09%*								3,726		529

	Total Common Stocks - 0.18%*									4,164		1,044

	Warrants
		Advertising
		STN Video Inc.	Class B Non-Voting Stock	6/30/2017	6/30/2027			191,500		246		—	(3)(7)
		Total Advertising - 0.00%*								246		—

		Application Software
		3DNA Corp. (dba NationBuilder)	Series C-1 Preferred Stock	12/28/2018	12/28/2028			273,164		104		—	(7)
		Aria Systems, Inc.	Series G Preferred Stock	6/29/2018	6/29/2028			2,387,705		1,048		2,290	(7)
		Circadence Corporation	Series A-6 Preferred Stock	12/20/2018	12/20/2028			1,538,462		3,630		83	(7)
			Series A-6 Preferred Stock	10/31/2019	10/31/2029			384,615		846		21	(7)
		Dtex Systems, Inc.	Series C-Prime Preferred Stock	6/1/2018	6/1/2025			500,000		59		195	(7)
			Series C-Prime Preferred Stock	7/11/2019	7/11/2026			833,333		115		325	(7)
		FiscalNote, Inc.	Earnout	7/29/2022	7/29/2027		N/A			127		80	(7)(13)(19)
		Porch Group, Inc.	Earnout	12/23/2020	12/23/2023		N/A			—		—	(7)(13)(15)
		Total Application Software - 0.52%*								5,929		2,994

		Biotechnology
		Mustang Bio, Inc.	Common Stock	3/4/2022	3/4/2032			748,036		315		53	(7)
		TRACON Pharmaceuticals, Inc.	Common Stock	9/2/2022	9/2/2032			150,753		226		211	(7)(15)
		Total Biotechnology - 0.05%*								541		264

		Computer & Electronics Retail
		Massdrop, Inc.	Series B Preferred Stock	7/22/2019	7/22/2029			848,093		183		—	(7)
		Total Computer & Electronics Retail - 0.00%*								183		—

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments (Unaudited) – (continued)

March 31, 2023

(In thousands, except share and per share data)


Portfolio Company			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares			Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Warrants
		Data Processing & Outsourced Services
		Interactions Corporation	Common Stock	6/24/2022	6/24/2032			189,408		219		131	(7)
		ShareThis, Inc.	Series D-3 Preferred Stock	12/3/2018	12/3/2028			647,615		2,162		1,403	(7)
		Total Data Processing & Outsourced Services - 0.27%*								2,381		1,534

		Electronic Equipment & Instruments
		Brivo, Inc.	Series A-2 Preferred Stock	10/20/2022	10/20/2032			201,000		98		95	(7)
		Epic IO Technologies, Inc.	Success fee	12/17/2021	12/17/2024		N/A			481		465	(7)(13)
		Total Electronic Equipment & Instruments - 0.10%*								579		560

		Health Care Equipment
		Moximed, Inc.	Series C Preferred Stock	6/24/2022	6/24/2032			214,285		175		175	(7)
		Revelle Aesthetics, Inc.	Series A-2 Preferred Stock	3/30/2022	3/30/2032			115,591		126		116	(7)
		Total Health Care Equipment - 0.05%*								301		291

		Health Care Technology
		Allurion Technologies, Inc.	Series C Preferred Stock	3/30/2021	3/30/2031			132,979		282		591	(7)
			Series D-1 Preferred Stock	6/14/2022	6/14/2032			44,220		141		50	(7)
			Series D-1 Preferred Stock	9/15/2022	9/15/2032			44,220		144		50	(7)
		EBR Systems, Inc.	Success fee	6/30/2022	6/30/2032		N/A			292		315	(7)(13)
		Mingle Healthcare Solutions, Inc.	Series CC Preferred Stock	8/15/2018	8/15/2028			1,770,973		492		—	(7)
		Nalu Medical, Inc.	Series D-2 Preferred Stock	10/12/2022	10/12/2032			91,717		173		109	(7)
		Route 92 Medical, Inc.	Success fee	8/17/2021	8/17/2031		N/A			258		306	(7)(13)
		SetPoint Medical Corporation	Series B Preferred Stock	6/29/2021	6/29/2031			400,000		14		87	(7)
			Series B Preferred Stock	12/29/2022	12/29/2032			600,000		74		131	(7)
		VERO Biotech LLC	Success fee	12/29/2020	12/29/2025		N/A			377		268	(7)(13)
		Total Health Care Technology - 0.33%*								2,247		1,907

		Human Resource & Employment Services
		CloudPay, Inc.	Series B Preferred Stock	6/30/2020	6/30/2030			11,273		218		903	(3)(7)(12)
			Series D Preferred Stock	8/17/2021	8/17/2031			6,129		160		168	(3)(7)(12)
		Snagajob.com, Inc.	Series B-1 Preferred Stock	9/29/2021	9/29/2031			763,269		343		40	(7)
		Total Human Resource & Employment Services - 0.20%*								721		1,111

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments (Unaudited) – (continued)

March 31, 2023

(In thousands, except share and per share data)


Portfolio Company			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares			Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Warrants
		Internet & Direct Marketing Retail
		Madison Reed, Inc.	Success fee	12/16/2022	N/A		N/A			132		132	(7)(13)
		Total Internet & Direct Marketing Retail - 0.02%*								132		132

		Internet Software and Services
		Bombora, Inc.	Common Stock	3/31/2021	3/31/2031			121,581		175		104	(7)
		Fidelis Cybersecurity, Inc.	Common Stock	3/25/2022	3/25/2032		N/A			79		115	(7)(16)
		INRIX, Inc.	Common Stock	7/26/2019	7/26/2029			150,804		522		1,194	(7)
		Longtail Ad Solutions, Inc. (dba JW Player)	Common Stock	12/12/2019	12/12/2029			387,596		47		349	(7)
		Skillshare, Inc.	Success fee	11/8/2022	11/8/2026		N/A			243		262	(7)(13)
		Synack, Inc.	Common Stock	6/30/2022	6/30/2032			102,363		129		116	(7)
		Total Internet Software and Services - 0.38%*								1,195		2,140

		Property & Casualty Insurance
		Kin Insurance, Inc.	Series D-3 Preferred Stock	9/26/2022	9/26/2032			41,576		302		299	(7)
		Total Property & Casualty Insurance - 0.05%*								302		299

		Specialized Consumer Services
		AllClear ID, Inc.	Common Stock	9/1/2017	9/1/2027			523,893		1,053		—	(7)
			Common Stock	10/17/2018	10/17/2028			346,621		697		—	(7)
		Credit Sesame, Inc.	Common Stock	1/7/2020	1/7/2030			191,601		425		366	(7)
		Total Specialized Consumer Services - 0.06%*								2,175		366

		System Software
		Dejero Labs Inc.	Common Stock	5/31/2019	5/31/2029			333,621		192		227	(3)(7)(10)
		Scale Computing, Inc.	Common Stock	3/29/2019	3/29/2029			9,665,667		346		—	(7)
		Total System Software - 0.04%*								538		227

		Technology Hardware, Storage & Peripherals
		RealWear, Inc.	Series A Preferred Stock	10/5/2018	10/5/2028			112,451		136		556	(7)
			Series A Preferred Stock	12/28/2018	12/28/2028			22,491		25		111	(7)
			Series A Preferred Stock	6/27/2019	6/27/2029			123,894		381		612	(7)
		Total Technology Hardware, Storage & Peripherals - 0.23%*								542		1,279

	Total Warrants - 2.30%*									18,012		13,104
Total Non-Control/Non-Affiliate Investments - 187.19%*										1,080,015		1,066,654

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments (Unaudited) – (continued)

March 31, 2023

(In thousands, except share and per share data)


Portfolio Company			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares		Cost ($)		Fair Value ($) (2),(6)		Footnotes
Affiliate Investments												(18)
	Senior Secured Term Loans
		Health Care Technology
		Gynesonics, Inc.	SOFR+8.75%, 8.00% ceiling, 5.00% ETP	3/1/2023	11/30/2026		25,595		25,664		23,146	(8)
		Total Health Care Technology - 4.06%*							25,664		23,146

	Total Senior Secured Term Loans - 4.06%*								25,664		23,146

	Preferred Stocks
		Health Care Technology
		Gynesonics, Inc.	Series A-2 Preferred Stock	3/1/2023	N/A		3,266,668		25,000		21,821	(7)
		Total Health Care Technology - 3.83%*							25,000		21,821

	Total Preferred Stocks - 3.83%*								25,000		21,821

	Common Stocks
		Application Software
		Coginiti Corp		3/9/2020	N/A		1,040,160		4,551		921	(7)
		Total Application Software - 0.16%*							4,551		921

	Total Common Stocks - 0.16%*								4,551		921

	Warrants
		Application Software
		Coginiti Corp	Common Stock	3/9/2020	3/9/2030		811,770		—		874	(7)
		Total Application Software - 0.15%*							—		874

		Health Care Technology
		Gynesonics, Inc.	Success fee	3/1/2023	3/1/2030		—		313		313	(7)(13)
		Total Health Care Technology - 0.06%*							313		313

	Total Warrants - 0.21%*								313		1,187
Total Affiliate Investments - 8.26%*									55,528		47,075
Control Investments												(14)
	Senior Secured Term Loans
		Data Processing & Outsourced Services
		Pivot3, Inc.	LIBOR+8.50% PIK, 11.00% floor, 4.00% ETP	5/13/2019	4/15/2023		18,598		19,172		11,613	(4)(7)
		Total Data Processing & Outsourced Services - 2.04%*							19,172		11,613

	Total Senior Secured Term Loans - 2.04%*								19,172		11,613
Total Control Investments - 2.04%*									19,172		11,613

U.S. Treasury
			U.S. Treasury Bill, 4.515%	3/31/2023	4/6/2023		35,000		34,978		34,974
Total U.S. Treasury - 6.14%*									34,978		34,974
Total Investments - 203.63%*								$	1,189,693	$	1,160,316

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments (Unaudited) – (continued)

March 31, 2023

(1)

Disclosures of interest rates on notes include cash interest rates and payment-in-kind (“PIK”) interest rates, as applicable. Unless otherwise indicated, all of the Company’s variable rate debt investments bear interest at a rate that is determined by reference to the 3‑Month London Interbank Offered Rate (“LIBOR”), the U.S. Prime Rate, or the 3-Month Secured Overnight Financing Rate ("SOFR"). At March 31, 2023, the 3‑Month LIBOR was 5.19%, the U.S. Prime Rate was 8.00% and the 3-Month SOFR was 4.91%.

(2)

The Company’s investments are generally acquired in private transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”) and, therefore, except as otherwise noted, are subject to limitation on resale, may be deemed to be “restricted securities” under the Securities Act, and were valued at fair value as determined in good faith by the Company’s Board of Directors.

(3)

Investment is not a qualifying asset as defined under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). Non-qualifying assets at fair value represent 10.38% of total assets as of March 31, 2023. Qualifying assets must represent at least 70% of total assets at the time of acquisition of any additional non-qualifying assets. If at any time qualifying assets do not represent at least 70% of the Company’s total assets, the Company will be precluded from acquiring any additional non-qualifying assets until such time as it complies with the requirements of Section 55(a) of the 1940 Act.

(4)

Represents a PIK security. PIK interest is accrued and will be paid at maturity.

(5)

Disclosures of end-of-term-payments (“ETP”) are one-time payments stated as a percentage of original principal amount.

(6)

Investments are held at Fair Value net of the Fair Value of Unfunded Commitments. Refer to Note 3 for additional detail.

(7)

Investments are non-income producing.

(8)

The investment is an eligible loan investment in the collateral under the Credit Facility (as defined in Note 11).

(9)

All investments are domiciled in the United States, unless otherwise noted.

(10)

Investment is domiciled in Canada.

(11)

Investment is domiciled in Germany.

(12)

Investment is domiciled in the United Kingdom.

(13)

Investment is either a cash success fee payable or earnout of shares based on the consummation of certain trigger events.

(14)

Control investment, as defined under the 1940 Act, in which the Company owns more than 25% of the investment’s voting securities or has greater than 50% representation on its board.

(15)

Investment is publicly traded and listed on NASDAQ.

(16)

The warrant count is based upon a percentage of ownership of Fidelis Cybersecurity, Inc.

(17)

Investment is not a “restricted security” under the Securities Act.

(18)

Affiliate investment as defined under the 1940 Act in which the Company owns between 5% and 25% (inclusive) of the investment's voting securities and does not have rights to maintain greater than 50% representation on the board.

(19)

Investment is publicly traded and listed on NYSE.

* Value as a percentage of net assets.

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments (Unaudited) – (continued)

March 31, 2023

(In thousands, except share and per share data)

The Company classifies its investment portfolio by level of affiliation and control in accordance with the requirements of the 1940 Act. As defined in the 1940 Act, investee companies are deemed as affiliated investments when a company or individual possesses, or has the right to acquire within 60 days or less, beneficial ownership of 5.0% or more of the outstanding voting securities of an investee company. Control investments are those where the investor has the ability or power to exercise a controlling influence over the management or policies of an investee company. Control is generally deemed to exist when a company or individual possesses, or has the right to acquire within 60 days or less, beneficial ownership of more than 25.0% of the outstanding voting securities of an investee company, or maintains greater than 50% representation on the investee company's board of directors. Transactions related to the Company’s affiliate and control investments during the three months ended March 31, 2023 are as follows:


		For the Three Months Ended March 31, 2023
		Amount of Investment Income Earned 2022		Fair Value as of December 31, 2022		Gross Additions(1)		Gross Reductions(2)		Net Realized Gains (Losses)		Net Change in Unrealized Appreciation (Depreciation)			Fair Value as of March 31, 2023(3)
Portfolio Company	Investment Description
Affiliate Investments
Senior Secured Term Loans
Gynesonics, Inc.	SOFR+8.75%, 8.00% ceiling, 5.00% ETP, due 11/30/2026	$	292	$	—	$	25,664	$		$		$	(2,518	)	$	23,146
Total Senior Secured Term Loans			292		—		25,664		—		—		(2,518	)		23,146
Preferred Stocks
Gynesonics, Inc.	Series A-2 Preferred Stock		—		—		25,000		—		—		(3,179	)		21,821
Total Preferred Stocks			—		—		25,000		—		—		(3,179	)		21,821
Common Stocks
Coginiti Corp	Common Stock		—		1,174		—		—		—		(253	)		921
Total Common Stocks			—		1,174		—		—		—		(253	)		921
Warrants
Coginiti Corp	Warrant for common stock, expires 3/09/2030		—		910		—		—		—		(36	)		874
Gynesonics, Inc.	Success fee		—		—		313		—		—		—			313
Total Warrants			—		910		313		—		—		(36	)		1,187
Total Affiliate Investments		$	292	$	2,084	$	50,977	$	—	$	—	$	(5,986	)	$	47,075
Control Investments
Senior Secured Term Loans
Pivot3, Inc.	LIBOR+8.50% PIK, 11.00% floor, 4.00% ETP, due 4/15/2023		—		9,290		—		—		—		2,323			11,613
Total Senior Secured Term Loans			—		9,290		—		—		—		2,323			11,613
Total Control Investments		$	—	$	9,290	$	—	$	—	$	—	$	2,323		$	11,613

(1)

Gross additions includes increases in the basis of investments resulting from new portfolio investments, PIK interest, accretion of original issue discount (“OID”), the exchange of one or more existing investments for one or more new investments and the movement of an existing portfolio company into this category from a different category.

(2)

Gross reductions include decreases in the basis of investments resulting from principal collections related to investment repayments or sales, the exchange of one or more existing investments for one or more new investments and the movement of an existing portfolio company out of this category into a different category.

(3)

All investments in the portfolio companies, which as of March 31, 2023 represented 10.30% of the Company’s net assets, are restricted as to resale and were valued at fair value as determined in good faith by the Company’s Board of Directors.

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments (Unaudited) – (continued)

March 31, 2023

(In thousands, except share and per share data)

The following tables show the fair value of the Company's portfolio of investments by geographic region and industry as of March 31, 2023:


	Investments at Fair Value (Unaudited)
Geographic Region	Investments at Fair Value		Percentage of Net Assets
Northeastern United States	$	354,925		62.28	%
Western United States		338,300		59.37
South Central United States		84,526		14.83
Southeastern United States		78,857		13.84
Midwestern United States		75,005		13.16
Northwestern United States		72,474		12.72
United Kingdom		60,831		10.68
Germany		46,490		8.16
Canada		13,934		2.45
Total	$	1,125,342		197.49	%


	March 31, 2023 (Unaudited)
Industry	Investments at Fair Value		Percentage of Net Assets
Health Care Technology	$	238,813		41.91	%
Application Software		182,645		32.04
Internet Software and Services		147,192		25.84
Data Processing & Outsourced Services		99,263		17.42
Human Resource & Employment Services		97,957		17.20
Electronic Equipment & Instruments		86,844		15.24
System Software		81,875		14.37
Internet & Direct Marketing Retail		56,005		9.82
Property & Casualty Insurance		49,608		8.70
Biotechnology		30,062		5.28
Health Care Equipment		27,506		4.83
Education Services		25,398		4.46
Technology Hardware, Storage & Peripherals		1,808		0.32
Specialized Consumer Services		366		0.06
Total	$	1,125,342		197.49	%

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments

December 31, 2022

(In thousands, except share and per share data)


Portfolio Companies			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares		Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Senior Secured Term Loans
		Application Software
		Circadence Corporation	SOFR+9.50% PIK, 12.26% floor, 7.50% ETP	12/20/2018	12/15/2023		19,928		21,260		17,083	(4)(8)
		Dtex Systems, Inc.	SOFR+9.25%, 9.75% floor, 1.75% ETP	6/1/2021	6/1/2025		10,000		10,033		10,033	(8)
		FiscalNote, Inc.	PRIME+5.00%, 9.00% floor, 1.00% PIK, 4.25% ETP	10/19/2020	7/15/2027		39,151		38,655		38,655	(4)(8)
			PRIME+5.00%, 9.00% floor, 1.00% PIK, 4.25% ETP	9/30/2021	7/15/2027		8,700		8,663		8,663	(4)(8)
			PRIME+5.00%, 9.00% floor, 1.00% PIK, 4.25% ETP	3/28/2022	7/15/2027		17,400		17,148		17,148	(4)(8)
		VTX Intermediate Holdings, Inc. (dba VertexOne)	SOFR+9.00%, 9.50% floor, 4.50% ETP	12/28/2021	12/28/2026		75,000		75,033		75,033	(8)
			SOFR+9.00%, 9.50% floor, 4.50% ETP	5/31/2022	12/28/2026		10,000		9,967		9,967	(8)
		Total Application Software - 30.66%*							180,759		176,582

		Biotechnology
		Mustang Bio, Inc.	SOFR+8.75%, 9.25% floor, 3.50% ETP	3/4/2022	4/15/2027		30,000		29,709		29,709	(8)
		TRACON Pharmaceuticals, Inc.	PRIME+5.00%, 8.50% floor, 4.25% ETP	9/2/2022	9/1/2026		10,000		9,795		10,000	(8)
		Total Biotechnology - 6.89%*							39,504		39,709

		Data Processing & Outsourced Services
		Interactions Corporation	SOFR+9.26%, 9.76% floor, 3.4375% ETP	6/24/2022	6/15/2027		40,000		39,504		39,504	(8)
		ShareThis, Inc.	SOFR+9.25%, 11.86% floor, 3.00% ETP	12/3/2018	7/15/2025		19,250		19,710		19,388	(8)
			SOFR+9.25%, 11.86% floor, 3.00% ETP	1/7/2019	7/15/2025		750		768		755	(8)
			SOFR+9.25%, 11.86% floor, 3.00% ETP	7/24/2019	7/15/2025		1,000		1,022		1,007	(8)
			SOFR+8.25%, 10.86% floor, 3.00% ETP	8/18/2020	7/15/2025		1,000		1,026		1,007	(8)
		Vesta Payment Solutions, Inc.	SOFR+7.00%, 9.00% floor, 3.00% ETP	11/29/2022	11/15/2026		25,000		24,521		24,521	(8)
		Total Data Processing & Outsourced Services - 14.96%*							86,551		86,182

		Education Services
		Turning Tech Intermediate, Inc. (dba Echo 360, Inc.)	SOFR+8.50%, 9.00% floor, 13.00% cash cap, 3.00% ETP	6/22/2021	12/14/2025		20,000		20,266		20,266	(4)(8)
			SOFR+8.50%, 9.00% floor, 13.00% cash cap, 3.00% ETP	3/28/2022	12/14/2025		5,000		5,039		5,039	(4)(8)
		Total Education Services - 4.39%*							25,305		25,305

		Electronic Equipment & Instruments
		Brivo, Inc.	SOFR+6.85%, 10.89% floor, 50% of interest PIK, 3.00% ETP	10/20/2022	10/20/2027		44,378		43,912		43,912	(4)(8)
		Intellisite Holdings, Inc. (dba Epic IO Technologies, Inc.)	SOFR+9.75%, 10.25% floor, 2.00% ETP	12/17/2021	12/17/2025		19,000		18,788		18,788
			SOFR+9.75%, 10.25% floor, 2.00% ETP	2/28/2022	12/17/2025		3,000		2,989		2,989
			SOFR+9.75%, 10.25% floor, 2.00% ETP	3/29/2022	12/17/2025		5,000		4,970		4,970
			SOFR+9.75%, 10.25% floor, 2.00% ETP	7/19/2022	12/17/2025		3,000		2,976		2,976
			SOFR+9.75%, 10.25% floor, 2.00% ETP	11/16/2022	12/17/2025		2,000		1,958		1,958
			SOFR+9.75%, 10.25% floor, 2.00% ETP	12/27/2022	12/17/2025		2,000		1,958		1,958
		Total Electronic Equipment & Instruments - 13.46%*							77,551		77,551

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments – (continued)

December 31, 2022

(In thousands, except share and per share data)


Portfolio Companies			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares		Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Senior Secured Term Loans
		Health Care Equipment
		Moximed, Inc.	PRIME+5.25%, 8.75% floor, 3.50% ETP	6/24/2022	7/1/2027		15,000		14,772		14,772	(8)
		Revelle Aesthetics, Inc.	PRIME+5.50%, 8.75% floor, 4.00% ETP	3/30/2022	4/1/2027		12,500		12,377		12,377	(8)
		Total Health Care Equipment - 4.71%*							27,149		27,149

		Health Care Technology
		Allurion Technologies, Inc.	PRIME+6.44%, 9.50% floor, 3.00% ETP	12/30/2021	12/30/2026		5,000		4,917		4,917	(8)
			PRIME+6.44%, 9.50% floor, 3.00% ETP	12/30/2021	12/30/2026		20,000		20,151		20,151	(8)
			PRIME+6.44%, 9.50% floor, 3.00% ETP	6/14/2022	12/30/2026		15,000		14,850		14,850	(8)
			PRIME+6.44%, 9.50% floor, 3.00% ETP	10/27/2022	12/30/2026		15,000		14,797		14,797	(8)
		EBR Systems, Inc.	PRIME+4.90%, 8.90% floor, 4.50% ETP	6/30/2022	6/15/2027		20,000		19,648		19,648	(8)
		Gynesonics, Inc.	SOFR+8.75%, 9.25% floor, 3.50% ETP	12/1/2020	12/1/2025		30,000		30,135		30,135	(8)
			SOFR+8.75%, 9.25% floor, 3.50% ETP	8/30/2022	12/1/2025		20,000		19,887		19,887	(8)
		Mingle Healthcare Solutions, Inc.	SOFR+9.50%, 12.01% floor, .25% PIK, 10.50% ETP	8/15/2018	12/15/2023		4,015		4,615		3,821	(4)(8)
		Nalu Medical, Inc.	PRIME+2.70%, 6.70% floor, 2.00% PIK, 4.50% ETP	10/12/2022	10/12/2027		20,071		19,756		19,756	(4)(8)
		Route 92 Medical, Inc.	SOFR+8.48%, 8.98% floor, 3.95% ETP	8/17/2021	7/1/2026		13,000		12,843		12,843	(8)
		SetPoint Medical Corporation	SOFR+5.75%, 9.00% floor, 4.00% ETP	12/29/2022	12/1/2027		25,000		24,802		24,802	(8)
		VERO Biotech LLC	SOFR+9.05%, 9.55% floor, 3.00% ETP	12/29/2020	12/1/2024		25,000		25,125		25,125	(8)
			SOFR+9.05%, 9.55% floor, 3.00% ETP	3/30/2021	12/1/2024		15,000		15,183		15,183	(8)
		Total Health Care Technology - 39.22%*							226,709		225,915

		Human Resource & Employment Services
		CloudPay, Inc.	PRIME+6.25%, 10.25% floor, 2.00% ETP	9/26/2022	8/17/2027		60,000		59,693		59,693	(3)(8)(12)
		Snagajob.com, Inc.	SOFR+8.50%, 9.00% floor, 9.00% cash cap, 2.75% ETP	9/29/2021	9/1/2025		37,609		37,574		36,785	(4)(8)
		Total Human Resource & Employment Services - 16.75%*							97,267		96,478

		Internet & Direct Marketing Retail
		Madison Reed, Inc.	PRIME+4.75%, 11.00% floor, 3.00% ETP	12/16/2022	12/16/2026		9,600		9,353		9,353	(8)
		Marley Spoon AG	SOFR+8.50%, 1.25% PIK, 9.26% floor	6/30/2021	6/15/2025		26,780		26,567		26,567	(3)(4)(8)(11)
			SOFR+8.50%, 1.25% PIK, 9.26% floor	12/29/2021	6/15/2025		8,199		8,158		8,158	(3)(4)(8)(11)
			SOFR+8.50%, 1.25% PIK, 9.26% floor	6/14/2022	6/15/2025		11,775		11,775		11,775	(3)(4)(8)(11)
		Total Internet & Direct Marketing Retail - 9.70%*							55,853		55,853

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments – (continued)

December 31, 2022

(In thousands, except share and per share data)


Portfolio Companies			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares		Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Senior Secured Term Loans
		Internet Software and Services
		Bombora, Inc.	SOFR+5.00%, 5.76% floor, 3.75% PIK, 2.00% ETP	3/31/2021	3/31/2025		21,341		21,337		21,337	(4)(8)
		Fidelis Cybersecurity, Inc.	SOFR+11.00%, 12.00% floor, 2.39% ETP	5/13/2021	5/13/2024		12,205		12,360		11,857	(8)
			SOFR+11.00%, 12.00% floor, 2.00% ETP	3/25/2022	5/13/2024		8,947		8,986		8,692	(8)
		INRIX, Inc.	SOFR+9.00%, 9.76% floor, 2.50% ETP	11/15/2021	11/15/2025		40,000		40,296		40,296	(8)
			SOFR+9.00%, 9.76% floor, 2.50% ETP	5/3/2022	11/15/2025		5,000		5,033		5,033	(8)
		Skillshare, Inc.	SOFR+6.50%, 10.72% floor, 3.00% ETP	11/8/2022	11/8/2026		25,000		24,414		24,414	(8)
		Synack, Inc.	PRIME+4.25%, 8.25% floor	6/30/2022	6/30/2027		35,000		34,906		34,906	(8)
		Total Internet Software and Services - 25.44%*							147,332		146,535

		Property & Casualty Insurance
		Kin Insurance, Inc.	PRIME+6.25%, 12.50% floor, 3.00% ETP	9/26/2022	9/15/2026		50,000		49,143		49,143	(8)
		Total Property & Casualty Insurance - 8.53%*							49,143		49,143

		System Software
		3PL Central LLC	SOFR+4.50%, 6.50 floor, 2.50% PIK, 2.00% ETP	11/9/2022	11/9/2027		65,163		64,429		64,429	(4)(8)
		Total System Software - 11.18%*							64,429		64,429

	Total Senior Secured Term Loans - 185.89%*								1,077,552		1,070,831

	Second Lien Term Loans
		System Software
		Dejero Labs Inc.	SOFR+5.00%, 5.50 floor, 5.00% PIK, 3.00% ETP	12/22/2021	12/22/2025		13,661		13,654		13,654	(3)(4)(8)(10)
		Total System Software - 2.37%*							13,654		13,654

	Total Second Lien Term Loans - 2.37%*								13,654		13,654

	Preferred Stocks
		Application Software
		Aria Systems, Inc.	Series G	7/10/2018	N/A		289,419		250		347	(7)
		Total Application Software - 0.06%*							250		347

		Health Care Technology
		CareCloud, Inc.	11% Series A Cumulative Redeemable Perpetual	1/8/2020	N/A		462,064		12,132		12,335	(15)(17)
		Total Health Care Technology - 2.14%*							12,132		12,335

	Total Preferred Stocks - 2.20%*								12,382		12,682

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments – (continued)

December 31, 2022

(In thousands, except share and per share data)


Portfolio Companies			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares		Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Common Stocks
		Application Software
		FiscalNote, Inc.		10/19/2020	N/A		230,881		438		1,422	(7)(19)
		Total Application Software - 0.25%*							438		1,422

		Technology Hardware, Storage & Peripherals
		Quantum Corporation		8/13/2021	N/A		459,720		2,607		501	(3)(7)(15)(17)
		zSpace, Inc.		12/31/2020	N/A		6,078,499		1,119		-	(7)
		Total Technology Hardware, Storage & Peripherals - 0.09%*							3,726		501

	Total Common Stocks - 0.33%*								4,164		1,923

	Warrants
		Advertising
		STN Video Inc.	Class B Non-Voting Stock	6/30/2017	6/30/2027		191,500		246		—	(3)(7)
		Total Advertising - 0.00%*							246		—

		Application Software
		3DNA Corp. (dba NationBuilder)	Series C-1 Preferred Stock	12/28/2018	12/28/2028		273,164		104		-	(7)
		Aria Systems, Inc.	Series G Preferred Stock	6/29/2018	6/29/2028		2,387,705		1,048		2,865	(7)
		Circadence Corporation	Series A-6 Preferred Stock	12/20/2018	12/20/2028		1,538,462		3,630		87	(7)
			Series A-6 Preferred Stock	10/31/2019	10/31/2029		384,615		845		22	(7)
		Dtex Systems, Inc.	Series C-Prime Preferred Stock	6/1/2018	6/1/2025		500,000		59		214	(7)
			Series C-Prime Preferred Stock	7/11/2019	7/11/2026		833,333		115		356	(7)
		FiscalNote, Inc.	Earnout	7/29/2022	7/29/2027		—		127		105	(7)(13)(19)
		Porch Group, Inc.	Earnout	12/23/2020	12/23/2023		—		—		—	(7)(13)(15)
		Total Application Software - 0.63%*							5,928		3,649

		Biotechnology
		Mustang Bio, Inc.	Common Stock	3/4/2022	3/4/2032		748,036		315		59	(7)
		TRACON Pharmaceuticals, Inc.	Common Stock	9/2/2022	9/2/2032		150,753		226		157	(7)(15)
		Total Biotechnology - 0.04%*							541		216

		Computer & Electronics Retail
		Massdrop, Inc.	Series B Preferred Stock	7/22/2019	7/22/2029		848,093		183		68	(7)
		Total Computer & Electronics Retail - 0.01%*							183		68

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments – (continued)

December 31, 2022

(In thousands, except share and per share data)


Portfolio Companies			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares		Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Warrants
		Data Processing & Outsourced Services
		Interactions Corporation	Common Stock	6/24/2022	6/24/2032		189,408		219		204	(7)
		ShareThis, Inc.	Series D-3 Preferred Stock	12/3/2018	12/3/2028		647,615		2,162		1,728	(7)
		Total Data Processing & Outsourced Services - 0.34%*							2,381		1,932

		Electronic Equipment & Instruments
		Brivo, Inc.	Series A-2 Preferred Stock	10/20/2022	10/20/2032		201,000		98		107	(7)
		Epic IO Technologies, Inc.	Success fee	12/17/2021	12/17/2024		—		430		456	(7)(13)
		Total Electronic Equipment & Instruments - 0.10%*							528		563

		Health Care Equipment
		Moximed, Inc.	Series C Preferred Stock	6/24/2022	6/24/2032		214,285		175		163	(7)
		Revelle Aesthetics, Inc.	Series A-2 Preferred Stock	3/30/2022	3/30/3032		115,591		127		121	(7)
		Total Health Care Equipment - 0.05%*							302		284

		Health Care Technology
		Allurion Technologies, Inc.	Series C Preferred Stock	3/30/2021	3/30/2031		132,979		283		632	(7)
			Series D-1 Preferred Stock	6/14/2022	3/30/2031		88,440		284		259	(7)
		CareCloud, Inc.	Common Stock	1/8/2020	1/8/2023		1,000,000		837		-	(7)
		EBR Systems, Inc.	Success fee	6/30/2022	6/30/2032		—		292		305	(7)(13)
		Gynesonics, Inc.	Series G Convertible Preferred Stock	11/19/2021	11/19/2031		27,978,115		341		446	(7)
		Mingle Healthcare Solutions, Inc.	Series CC Preferred Stock	8/15/2018	8/15/2028		1,770,973		492		-	(7)
		Nalu Medical, Inc.	Series D-2 Preferred Stock	10/12/2022	10/12/2032		91,717		173		137	(7)
		Route 92 Medical, Inc.	Success fee	8/17/2021	8/17/2031		—		248		297	(7)(13)
		SetPoint Medical Corporation	Series B Preferred Stock	6/29/2021	6/29/2031		400,000		14		50	(7)
			Series B Preferred Stock	12/29/2022	12/29/2032		600,000		74		74	(7)
		VERO Biotech LLC	Success fee	12/29/2020	12/29/2025		—		377		394	(7)(13)
		Total Health Care Technology - 0.45%*							3,415		2,594

		Human Resource & Employment Services
		CloudPay, Inc.	Series B Preferred Stock	6/30/2020	6/30/2030		11,273		218		920	(3)(7)(12)
			Series D Preferred Stock	8/17/2021	8/17/2031		6,129		160		170	(3)(7)(12)
		Snagajob.com, Inc.	Series B-1 Preferred Stock	9/29/2021	9/29/2031		763,269		343		220	(7)
		Total Human Resource & Employment Services - 0.23%*							721		1,310

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments – (continued)

December 31, 2022

(In thousands, except share and per share data)


Portfolio Companies			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares		Cost ($)		Fair Value ($) (2),(6)		Footnotes
Non-Control/Non-Affiliate Investments
	Warrants
		Internet & Direct Marketing Retail
		Madison Reed, Inc.	Success fee	12/16/2022	N/A		—		132		133	(7)(13)
		Total Internet & Direct Marketing Retail - 0.02%*							132		133

		Internet Software and Services
		Bombora, Inc.	Common Stock	3/31/2021	3/31/2031		121,581		175		248	(7)
		Fidelis Cybersecurity, Inc.	Common Stock	3/25/2022	3/25/2032		—		79		100	(7)(16)
		INRIX, Inc.	Common Stock	7/26/2019	7/26/2029		150,804		522		2,198	(7)
		Longtail Ad Solutions, Inc. (dba JW Player)	Common Stock	12/12/2019	12/12/2029		387,596		47		345	(7)
		Skillshare, Inc.	Success fee	11/8/2022	11/8/2026		—		243		225	(7)(13)
		Synack, Inc.	Common Stock	6/30/2022	6/30/2032		100,645		127		129	(7)
		Total Internet Software and Services - 0.56%*							1,193		3,245

		Property & Casualty Insurance
		Kin Insurance, Inc.	Series D-3 Preferred Stock	9/26/2022	9/26/2032		41,576		302		297	(7)
		Total Property & Casualty Insurance - 0.05%*							302		297

		Specialized Consumer Services
		AllClear ID, Inc.	Common Stock	9/1/2017	9/1/2027		870,514		1,750		—	(7)
		Credit Sesame, Inc.	Common Stock	1/7/2020	1/7/2030		191,601		425		796	(7)
		Total Specialized Consumer Services - 0.14%*							2,175		796

		System Software
		Dejero Labs Inc.	Common Stock	5/31/2019	5/31/2029		333,621		192		191	(3)(7)(10)
		Scale Computing, Inc.	Common Stock	3/29/2019	3/29/2029		9,665,667		346		—	(7)
		Total System Software - 0.03%*							538		191

		Technology Hardware, Storage & Peripherals
		RealWear, Inc.	Series A Preferred Stock	10/5/2018	10/5/2028		112,451		136		246	(7)
			Series A Preferred Stock	12/28/2018	12/28/2028		22,491		25		49	(7)
			Series A Preferred Stock	6/27/2019	6/27/2029		123,894		381		272	(7)
		Total Technology Hardware, Storage & Peripherals - 0.10%*							542		567

	Total Warrants - 2.75%*								19,127		15,845
Total Non-Control/Non-Affiliate Investments - 193.55%*									1,126,879		1,114,935

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments – (continued)

December 31, 2022


Portfolio Companies			Investment Description(1),(5),(9)	Acquisition Date	Maturity Date	Principal ($) / Shares		Cost ($)		Fair Value ($) (2),(6)		Footnotes
Affiliate Investments												(18)
	Common Stocks
		Application Software
		Coginiti Corp		3/9/2020	N/A		1,040,160		4,551		1,174	(7)
		Total Application Software - 0.20%*							4,551		1,174

	Total Common Stocks - 0.20%*								4,551		1,174

	Warrants
		Application Software
		Coginiti Corp	Common Stock	3/9/2020	3/9/2030		811,770		—		910	(7)
		Total Application Software - 0.16%*							—		910

	Total Warrants - 0.16%*								—		910
Total Affiliate Investments - 0.36%*									4,551		2,084
	Control Investments											(14)
	Senior Secured Term Loans
		Data Processing & Outsourced Services
		Pivot3, Inc.	LIBOR+8.50% PIK, 11.00% floor, 4.00% ETP	5/13/2019	1/15/2023		18,598		19,172		9,290	(4)(7)
		Total Data Processing & Outsourced Services - 1.61%*							19,172		9,290

	Total Senior Secured Term Loans - 1.61%*								19,172		9,290
Total Control Investments - 1.61%*									19,172		9,290
Total Investments - 195.52%*								$	1,150,602	$	1,126,309

(1)

Disclosures of interest rates on notes include cash interest rates and payment-in-kind (“PIK”) interest rates, as applicable. Unless otherwise indicated, all of the Company’s variable rate debt investments bear interest at a rate that is determined by reference to the 3‑Month London Interbank Offered Rate (“LIBOR”), the U.S. Prime Rate, or the 3-Month Secured Overnight Financing Rate ("SOFR"). At December 31, 2022, the 3‑Month LIBOR was 4.77%, the U.S. Prime Rate was 7.50%, and the 3-Month SOFR was 4.79%.

(2)

(3)

Investment is not a qualifying asset as defined under Section 55(a) of the Investment Company Act of 1940, as amended (the “1940 Act”). Non-qualifying assets at fair value represent 10.65% of total assets as of December 31, 2022. Qualifying assets must represent at least 70% of total assets at the time of acquisition of any additional non-qualifying assets. If at any time qualifying assets do not represent at least 70% of the Company’s total assets, the Company will be precluded from acquiring any additional non-qualifying assets until such time as it complies with the requirements of Section 55(a) of the 1940 Act.

(4)

Represents a PIK security. PIK interest is accrued and will be paid at maturity.

(5)

Disclosures of end-of-term-payments (“ETP”) are one-time payments stated as a percentage of original principal amount.

(6)

Investments are held at Fair Value net of the Fair Value of Unfunded Commitments. Refer to Note 3 for additional detail.

(7)

Investments are non-income producing.

(8)

The investment is an eligible loan investment in the collateral under the Credit Facility (as defined in Note 11

(9)

All investments are domiciled in the United States, unless otherwise noted.

(10)

Investment is domiciled in Canada.

(11)

Investment is domiciled in Germany.

(12)

Investment is domiciled in the United Kingdom.

(13)

Investment is either a cash success fee payable or earnout of shares based on the consummation of certain trigger events.

(14)

Control investment, as defined under the 1940 Act, in which the Company owns more than 25% of the investment’s voting securities or has greater than 50% representation on its board.

(15)

Investment is publicly traded and listed on NASDAQ.

(16)

The warrant count is based upon a percentage of ownership of Fidelis Cybersecurity, Inc.

(17)

Investment is not a “restricted security” under the Securities Act.

(18)

(19)

Investment is publicly traded and listed on NYSE.

* Value as a percentage of net assets.

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments – (continued)

December 31, 2022

(In thousands, except share and per share data)

The Company classifies its investment portfolio by level of affiliation and control in accordance with the requirements of the 1940 Act. As defined in the 1940 Act, investee companies are deemed as affiliated investments when a company or individual possesses, or has the right to acquire within 60 days or less, beneficial ownership of 5.0% or more of the outstanding voting securities of an investee company. Control investments are those where the investor has the ability or power to exercise a controlling influence over the management or policies of an investee company. Control is generally deemed to exist when a company or individual possesses, or has the right to acquire within 60 days or less, beneficial ownership of more than 25.0% of the outstanding voting securities of an investee company, or maintains greater than 50% representation on the investee company's board of directors. The Company’s affiliate and control investments as of December 31, 2022, along with the transactions during the year ended December 31, 2022 are as follows:


				For the Year Ended December 31, 2022
		Amount of Investment Income Earned 2022		Fair Value as of December 31, 2021		Gross Additions(1)		Gross Reductions(2)			Net Realized Gains (Losses)			Net Change in Unrealized Appreciation (Depreciation)			Fair Value as of December 31, 2022(3)
Portfolio Company	Investment Description
Affiliate Investments
Senior Secured Term Loans
Coginiti Corp	LIBOR+9.50% PIK, 10.81% floor, due 12/15/2022	$	109	$	—	$	930	$	(930	)	$	—		$	—		$	—
Total Senior Secured Term Loans			109		—		930		(930	)		—			—			—
Common Stocks
Coginiti Corp	Common Stock		—		—		4,551		—			—			(3,377	)		1,174
Total Common Stocks			—		—		4,551		—			—			(3,377	)		1,174
Warrants
Coginiti Corp	Warrant for Common Stock, exercise price $0.01/share, expires 3/9/2030		—		—		1,009		—			—			(99	)		910
Total Warrants			—		—		1,009		—			—			(99	)		910
Total Affiliate Investments		$	109	$	—	$	6,490	$	(930	)	$	—		$	(3,476	)	$	2,084
Control Investments
Senior Secured Term Loans
Mojix, Inc.	LIBOR+12.00% , 12.00% cash cap, 5% ETP, due 1/15/2025	$	2,287	$	7,568	$	1,987	$	(8,489	)	$	—		$	(1,066	)	$	—
	LIBOR+12.00% , 12.00% cash cap, 5% ETP, due 1/15/2025		744		2,523		647		(2,818	)		—			(352	)		—
	LIBOR+12.00% , 12.00% cash cap, 5% ETP, due 1/15/2025		184		630		160		(704	)		—			(86	)		—
	LIBOR+12.00% , 12.00% cash cap, 5% ETP, due 1/15/2025		185		629		161		(703	)		—			(87	)		—
	LIBOR+12.00% , 12.00% cash cap, 5% ETP, due 1/15/2025		374		1,253		327		(1,400	)		—			(180	)		—
	LIBOR+12.00% , 12.00% cash cap, 5% ETP, due 1/15/2025		291		1,008		266		(1,090	)		—			(184	)		—
Pivot3, Inc.	LIBOR+8.50% PIK, 11.00% floor, due 11/15/2022		—		14,650		—		—			—			(5,360	)		9,290
Total Senior Secured Term Loans			4,065		28,261		3,548		(15,204	)		—			(7,315	)		9,290
Preferred Stocks
Mojix, Inc.	Series A-1 Preferred Stock		32		870		—		(800	)		—			(70	)		—
Pivot3 Holdings, Inc.	Series 1 Preferred Stock		—		—		—		—			(2,000	)		2,000			—
Total Preferred Stocks			32		870		—		(800	)		(2,000	)		1,930			—
Warrants
Mojix, Inc.	Warrant for Common Stock, exercise price $1.286/share, expires 12/13/2030		—		—		—		(119	)		—			119			—
	Warrant for Common Stock, exercise price $2.1286/share, expires 12/13/2030		—		—		—		(298	)		—			298			—
	Warrant for Common Stock, exercise price $5.57338/share, expires 12/13/2030		—		—		—		(829	)		—			829			—
Total Warrants			—		—		—		(1,246	)		—			1,246			—
Total Control Investments		$	4,097	$	29,131	$	3,548	$	(17,250	)	$	(2,000	)	$	(4,139	)	$	9,290

(1)

(2)

Gross reductions include decreases in the basis of investments resulting from principal collections related to investment repayments or sales, the exchange of one or more existing Investments for one or more new investments and the movement of an existing portfolio company out of this category into a different category.

(3)

All investments in the portfolio company, which as of December 31, 2022 represented 1.97% of the Company’s net assets, are restricted as to resale and were valued at fair value as determined in good faith by the Company’s Board of Directors.

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Schedule of Investments – (continued)

December 31, 2022

(In thousands, except share and per share data)

The following tables show the fair value of the Company's portfolio of investments by geographic region and industry as of December 31, 2022:


	December 31, 2022
	Investments at		Percentage of
Geographic Region	Fair Value		Net Assets
Northeastern United States	$	351,654		61.04	%
Western United States		346,372		60.13
South Central United States		85,000		14.76
Southeastern United States		74,797		12.98
Midwestern United States		74,745		12.98
Northwestern United States		72,615		12.61
United Kingdom		60,783		10.55
Germany		46,499		8.07
Canada		13,844		2.40
Total	$	1,126,309		195.52	%


	December 31, 2022
	Investments at		Percentage of
Industry	Fair Value		Net Assets
Health Care Technology	$	240,844		41.81	%
Application Software		184,084		31.96
Internet Software and Services		149,780		26.00
Human Resource & Employment Services		97,788		16.98
Data Processing & Outsourced Services		97,404		16.91
System Software		78,274		13.58
Electronic Equipment & Instruments		78,114		13.56
Internet & Direct Marketing Retail		55,986		9.72
Property & Casualty Insurance		49,440		8.58
Biotechnology		39,925		6.93
Health Care Equipment		27,433		4.76
Education Services		25,305		4.39
Technology Hardware, Storage & Peripherals		1,068		0.19
Specialized Consumer Services		796		0.14
Computer & Electronics Retail		68		0.01
Total	$	1,126,309		195.52	%

See notes to financial statements.

Table of Contents

RUNWAY GROWTH FINANCE CORP.

Notes to Financial Statements

(Unaudited)

Note 1 – Organization

Runway Growth Finance Corp. (formerly known as Runway Growth Credit Fund Inc.) (the “Company”), is a Maryland corporation that was formed on August 31, 2015. On August 18, 2021, the Company changed its name to “Runway Growth Finance Corp.” from “Runway Growth Credit Fund Inc.” The Company is an externally managed, non-diversified, closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). In addition, the Company has elected to be treated, currently qualifies, and intends to continue to qualify annually as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”).

The Company was formed primarily to lend to, and selectively invest in, high growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products in other high-growth industries in the United States. The Company’s investment objective is to maximize its total return to its stockholders primarily through current income on its loan portfolio, and secondarily through capital appreciation on its warrants and other equity positions. The Company’s investment activities are managed by its external investment adviser, Runway Growth Capital LLC (“RGC”). The Company’s administrator, Runway Administrator Services LLC (the “Administrator”), is a wholly owned subsidiary of RGC and provides administrative services necessary for the Company to operate.

On October 25, 2021, the Company closed its initial public offering ("IPO"), issuing 6,850,000 shares of its common stock on the Nasdaq Global Select Market LLC under the symbol “RWAY”.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The accompanying interim unaudited financial statements of the Company are prepared on the accrual basis of accounting in conformity with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the requirements for reporting on Form 10‑Q and Regulation S-X under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company is an investment company following the specialized accounting and reporting guidance specified in the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 946, Financial Services — Investment Companies.

In the opinion of management, all adjustments, all of which were of a normal recurring nature, considered necessary for the fair presentation of financial statements for the interim period have been included. The results of operations for the current interim period are not necessarily indicative of results that ultimately may be achieved for any other interim period or for the year ending December 31, 2023. The interim unaudited financial statements and notes hereto should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s annual report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the "SEC") on March 2, 2023.

Certain items in the March 31, 2022 and December 31, 2022 financial statements have been reclassified to conform to the March 31, 2023 presentation with no effect on the net assets on the Statements of Assets and Liabilities, and no net effect on the net increase in net assets resulting from operations on the Statements of Operations.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates.

Table of Contents

Cash and Cash Equivalents

Cash represents deposits held at financial institutions, while cash equivalents are highly liquid investments held at financial institutions with an original maturity of three months or less at the date of acquisition. At times, the Company’s cash and cash equivalents exceed federally insured limits, subjecting the Company to risks related to the uninsured balance. Cash and cash equivalents are held at large, established, high credit-quality financial institutions, and management believes that risk of loss associated with any uninsured balance is remote.

Deferred Debt Costs

The Company records costs related to the issuance of debt obligations as deferred debt costs. These costs are deferred and amortized using the straight-line method over the stated maturity life of the obligations. Deferred debt costs associated with the Company's Credit Facility and unsecured notes are netted with the outstanding principal balance on the Company's Statement of Assets and Liabilities, unless there are no outstanding borrowings, in which case the deferred debt costs are presented as an asset. For more information, refer to “Note 11 – Borrowings.”

Reverse Repurchase Agreement

The Company has, and may in the future, enter into reverse repurchase agreements, under the terms of a master repurchase agreement, with selected commercial banks and broker-dealers, under which the Company acquires securities as collateral (debt obligation) subject to an obligation of the counterparty to repurchase and the Company to resell the securities (obligation) at an agreed upon time and price. The Company, through the custodian or a sub-custodian, receives delivery of the underlying securities collateralizing reverse repurchase agreements. The Company requires the custodian to take possession, to have legally segregated in the Federal Reserve Book Entry System, or to have segregated within the custodian’s vault, all securities held as collateral for reverse repurchase agreements. The Company and the counterparties are permitted to sell, re-pledge, or use the collateral associated with the transaction. It is the Company’s policy that the market value of the collateral be at least equal to 100% of the repurchase price in the case of a reverse repurchase agreement of one-day duration and 102% of the repurchase price in the case of all other reverse repurchase agreements. Upon an event of default under the terms of the master repurchase agreement, both parties have the right to set-off. If the seller defaults or enters an insolvency proceeding, realization of the collateral by the Company may be delayed, limited or wholly denied.

The Company had no outstanding reverse repurchase agreements at March 31, 2023 or December 31, 2022.

Investment Transactions and Related Investment Income

Security transactions, if any, are recorded on a trade-date basis. Realized gains or losses from the repayment or sale of investments are measured using the specific identification method. The amortized cost basis of investments represents the original cost adjusted for the accretion/amortization of discounts and premiums and upfront loan origination fees. The Company reports changes from the prior period in fair value of investments that are measured at fair value as a component of net change in unrealized appreciation (depreciation) on investments on the Statements of Operations.

Dividends are recorded on the ex-dividend date. Interest income, if any, adjusted for amortization of market premium and accretion of market discount, is recorded on an accrual basis to the extent that the Company expects to collect such amounts. Original issue discount (“OID”), principally representing the estimated fair value of detachable equity, warrants or contractual success fees obtained in conjunction with the Company’s debt investments, loan origination fees, end of term payments, and market discount or premium are capitalized and accreted or amortized into interest income over the life of the respective security using the effective interest method. Loan origination fees received in connection with the closing of investments are reported as unearned income, which is included as amortized cost of the investment; the unearned income from such fees is accreted into interest income over the contractual life of the loan based on the effective interest method. Upon prepayment of a debt investment, any unamortized loan origination fees, end-of-term payments, and unamortized market discounts are recorded as interest income and any prepayment penalties are recorded as fee income. Upon amending terms of an existing investment, any amendment fees charged are recorded as fee income.

Table of Contents

The Company currently holds, and expects to hold in the future, some investments in its portfolio that contain payment-in-kind (“PIK”) interest provisions. PIK interest is computed at the contractual rate specified in each loan agreement and is added to the principal balance of the loan, rather than being paid to the Company in cash, and is recorded as interest income. Thus, the actual collection of PIK interest may be deferred until the time of debt principal repayment. PIK interest, which is a non-cash source of income, is included in the Company’s taxable income and therefore affects the amount of income the Company is required to distribute to stockholders to maintain its qualification as a RIC for U.S. federal income tax purposes, even though the Company has not yet collected the cash. For the three months ended March 31, 2023, approximately 9.7% of the Company’s total investment income was attributable to non-cash PIK interest. For the three months ended March 31, 2022, approximately 7.4% of the Company’s total investment income was attributable to non-cash PIK interest.

Non-Accrual of Investments

Debt investments are placed on non-accrual status when principal, interest, and other obligations become materially past due or when there is reasonable doubt that principal, interest, or other obligations will be collected in full. At the point of non-accrual, the Company will cease recognizing interest income on the debt investment until all principal and interest due have been paid or the Company believes the borrower has demonstrated the ability to repay its current and future contractual obligations. Additionally, any OID associated with the debt investment is no longer accreted to interest income as of the date the loan is placed on non-accrual status. Any payments received on non-accrual loans are first applied to principal prior to recovery of any foregone interest or end of term payment fees. Non-accrual loans are restored to accrual status when past due principal or interest are paid, and, in management’s judgment are likely to remain current. The Company may make exceptions to this policy if the investment has sufficient collateral value and is in the process of collection such that the Company will be made whole on the investment, inclusive of interest and end of term payment fees.

As of March 31, 2023, and December 31, 2022, the Company has not written off any accrued and uncollected PIK interest. As of March 31, 2023, the Company had one loan to Pivot3, Inc. on non-accrual status. The loan, with a cost basis of $19.2 million and a fair value of $11.6 million, represents 1.00% of the Company’s total investment portfolio. From being placed on non-accrual status through March 31, 2023, cumulative interest of $4.3 million would be receivable and $0.3 million OID would be accreted into the cost basis, for a total of $4.6 million not recorded in interest income from control investments on the Statement of Operations. As of December 31, 2022, the Company had one loan to Pivot3, Inc. on non-accrual status. The loan, with a cost basis of $19.2 million and a fair market value of $9.3 million, represents 0.8% of the Company’s total investment portfolio. From being placed on non-accrual status through December 31, 2022, cumulative interest of $3.6 million would be payable and $0.3 million OID would be accreted into the cost basis, for a total of $3.9 million not recorded in interest income from control investments on the Statement of Operations.

Valuation of Investments

The Company measures the value of its investments at fair value in accordance with ASC Topic 820, Fair Value Measurements and Disclosure (“ASC Topic 820”), issued by the FASB. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The audit committee of the Company’s Board of Directors (the “Audit Committee”) assists the Board of Directors in valuing investments that are not publicly traded or for which current market values are not readily available. Investments for which market quotations are readily available are valued using market quotations, which are generally obtained from independent pricing services, broker-dealers or market makers. With respect to portfolio investments for which market quotations are not readily available, the Company’s Board of Directors, with the assistance of the Audit Committee, RGC and its senior investment team and independent valuation agents, is responsible for determining, in good faith, the fair value in accordance with the valuation policy approved by the Board of Directors. If more than one valuation method is used to measure fair value, the results are evaluated and weighted, as appropriate, considering the reasonableness of the range indicated by those results. The Company considers a range of fair values based upon the valuation techniques utilized and selects the value within that range that was most representative of fair value based on current market conditions as well as other factors RGC’s senior investment team considers relevant.

The Company’s Board of Directors makes this fair value determination on a quarterly basis and any other time when a decision regarding the fair value of the portfolio investments is required. A determination of fair value involves subjective judgments and estimates and depends on the facts and circumstances. Due to the inherent uncertainty of determining the fair value of portfolio investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material.

Table of Contents

ASC Topic 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. ASC Topic 820 also provides guidance regarding a fair value hierarchy, which prioritizes information used to measure fair value and the effect of fair value measurements on earnings and provides for enhanced disclosures determined by the level within the hierarchy of information used in the valuation. In accordance with ASC Topic 820, these inputs are summarized in the three levels listed below:

•

Level 1—Valuations are based on quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.

•

Level 2—Valuations are based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly and model-based valuation techniques for which all significant inputs are observable.

•

Level 3—Valuations based on inputs that are unobservable and significant to the overall fair value measurement. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models incorporating significant unobservable inputs, such as discounted cash flow models and other similar valuations techniques. The valuation of Level 3 assets and liabilities generally requires significant management judgment due to the inability to observe inputs to valuation.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an investment’s level within the fair value hierarchy is based on the lowest level of observable input that is significant to the fair value measurement. The assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the investment.

Under ASC Topic 820, the fair value measurement also assumes that the transaction to sell an asset occurs in the principal market for the asset or, in the absence of a principal market, the most advantageous market for the asset, which may be a hypothetical market, and excludes transaction costs. The principal market for any asset is the market with the greatest volume and level of activity for such asset in which the reporting entity would or could sell or transfer the asset. In determining the principal market for an asset or liability under ASC Topic 820, it is assumed that the reporting entity has access to such market as of the measurement date. Market participants are defined as buyers and sellers in the principal or most advantageous market that are independent, knowledgeable and willing and able to transact.

With respect to investments for which market quotations are not readily available, the Company undertakes a multi-step valuation process each quarter, as described below:

•

The quarterly valuation process begins with each portfolio company investment being initially valued by RGC’s investment professionals that are responsible for the portfolio investment;

•

Preliminary valuation conclusions are then documented and discussed with RGC’s senior investment team;

•

At least once annually, the valuation for each portfolio investment is reviewed by an independent valuation firm. Certain investments, however, may not be evaluated by an independent valuation firm if the net asset value and other aspects of such investments in the aggregate do not exceed certain thresholds;

•

The Audit Committee then reviews these preliminary valuations from RGC and the independent valuation firm, if any, and makes a recommendation to the Company’s Board of Directors regarding such valuations; and

•

The Company’s Board of Directors reviews the recommended preliminary valuations and determines the fair value of each investment in the Company’s portfolio, in good faith, based on the input of RGC, the independent valuation firm and the Audit Committee.

The Company’s investments are primarily loans made to and equity and warrants of small, fast-growing companies focused in technology, life sciences, health care information and services, business services, and other high-growth industries. These investments are considered Level 3 assets under ASC Topic 820 because there is no known or accessible market or market indices for these types of debt and equity instruments and, thus, RGC’s senior investment team must estimate the fair value of these investment securities based on models utilizing unobservable inputs.

Rule 2a-5 under the 1940 Act was adopted by the SEC in December 2020 and establishes requirements for determining fair value in good faith for purposes of the 1940 Act. Rule 2a-5 permits boards, subject to board oversight and certain other conditions, to designate certain parties to perform fair value determinations. Rule 2a-5 also defines when market quotations are "readily available" for purposes of the 1940 Act and the threshold for determining whether a fund must determine the fair value of a security. The SEC also adopted new Rule 31a-4 under the 1940 Act ("Rule 31a-4"), which provides the recordkeeping requirements associated with fair value determinations. Finally, the SEC rescinded previously issued guidance on related issues, including the role of the board in determining fair value and

Table of Contents

the accounting and auditing of fund investments. Rule 2a-5 and Rule 31a-4 became effective on March 8, 2021, and had a compliance date of September 8, 2022. While the board of directors has not elected to designate RGC as the valuation designee, the Company has adopted certain revisions to its valuation policies and procedures in order comply with the applicable requirements of Rule 2a-5 and Rule 31a-4.

Investment Valuation Techniques

Valuation methodologies involve a significant degree of judgment. There is no single standard for determining the fair value of investments that do not have an active public market. Valuations of privately held investments are inherently uncertain, as they are based on estimates, and their values may fluctuate over time. The determination of fair value may differ materially from the values that would have been used if an active market for these investments existed. In some cases, the fair value of such investments is best expressed as a range of values derived utilizing different methodologies from which a fair value may then be determined.

Debt Investments

To determine the fair value of the Company’s debt investments, the Company compares the cost basis of the debt investment, which includes OID, to the resulting fair value determined using a discounted cash flow model, unless another model is more appropriate based on the circumstances at the measurement date. The discounted cash flow approach entails analyzing the interest rate spreads for recently completed financing transactions that are similar in nature to the Company’s investments, in order to determine a comparable range of effective market interest rates for its investments. The range of interest rate spreads utilized is based on borrowers with similar credit profiles. All remaining expected cash flows of the investment are discounted using this range of interest rates to determine a range of fair values for the debt investment.

Under certain circumstances, the Company may use an alternative technique to value the debt investments to be acquired by the Company that better reflects the fair value of the investment, such as the price paid or realized in a recently completed transaction or a binding offer received in an arms-length transaction, the use of multiple probability-weighted cash flow models when the expected future cash flows contain elements of variability or estimates of proceeds that would be received in a liquidation scenario.

Warrants

Fair value of warrants is primarily determined using a Black Scholes option-pricing model. Privately held warrants and equity-related securities are valued based on an analysis of various factors including, but not limited to, the following:

•

Underlying enterprise value of the issuer is estimated based on information available, including any information regarding the most recent rounds of issuer funding. Valuation techniques to determine enterprise value include market multiple approaches, income approaches or approaches that utilize recent rounds of financing and the portfolio company’s capital structure to determine enterprise value. Valuation techniques are also utilized to allocate the enterprise fair value of a portfolio company to the specific class of common or preferred stock exercisable in the warrant. Such techniques take into account the rights and preferences of the portfolio company’s securities, expected exit scenarios, and volatility associated with such outcomes to allocate the fair value to the specific class of stock held in the portfolio. Such techniques include Option Pricing Models, or “OPM,” including back-solve techniques, Probability Weighted Expected Return Models, or “PWERM,” and other techniques as determined to be appropriate.

•

Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on comparable publicly traded companies within indices similar in nature to the underlying company issuing the warrant. Significant increases (decreases) in this unobservable input could result in a significantly lower (higher) fair value, but a significantly higher or lower fair value measurement of any of the Company’s portfolio investments may occur regardless of whether there is a significant increase or decrease in this unobservable input.

•

The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant. Significant increases (decreases) in this unobservable input could result in a significantly higher (lower) fair value, but a significantly higher or lower fair value measurement of any of the Company’s portfolio investments may occur regardless of whether there is a significant increase (decrease) in this unobservable input.

Table of Contents

•

Other adjustments, including a marketability discount on private company warrants, are estimated based on judgment about the general industry environment. Significant increases (decreases) in this unobservable input could result in a significantly lower (higher) fair value, but a significantly higher or lower fair value measurement of any of the Company’s portfolio investments may occur regardless of whether there is a significant increase (decrease) in this unobservable input.

•

Historical portfolio experience on cancellations and exercises of warrants are utilized as the basis for determining the estimated life of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or initial public offerings, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input could result in a significantly higher (lower) fair value, but a significantly higher or lower fair value measurement of any of the Company’s portfolio investments may occur regardless of whether there is a significant increase (decrease) in this unobservable input.

Under certain circumstances, the Company may use an alternative technique to value warrants that better reflects the warrants’ fair values, such as an expected settlement of a warrant in the near term, a model that incorporates a put feature associated with the warrant, or the price paid or realized in a recently completed transaction or binding offer received in an arms-length transaction. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.

Equity Investments

The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing subsequent to the Company’s investment. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. The Company may also reference comparable transactions and/or secondary market transactions in connection with its determination of fair value. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. These assets are recorded at fair value on a recurring basis.

Fair Value of Financial Instruments

In accordance with ASC Topic 820 — Fair Value Measurements and Disclosures (“ASC Topic 820”), the Company evaluates fair value of its financial instruments. With the exception of the Company’s borrowings, which are reported at cost, all assets and liabilities approximate fair value on the Statements of Assets and Liabilities due to their short maturity.

The fair value of the Company’s Credit Facility, December 2026 Notes, July 2027 Notes, August 2027 Notes, and December 2027 Notes (as defined in "Note 11 - Borrowings") is estimated using the relative market yield approach. The fair value of the Company's Credit Facility, December 2026 Notes and August 2027 Notes are estimated using Level 3 inputs by discounting remaining payments using comparable market rates or market quotes for similar instruments at the measurement date. The fair value of the Company's July 2027 Notes and December 2027 Notes is based on vendor pricing received by the Company, which is considered a Level 2 input, and reflects the market close price of the notes traded on the Nasdaq Global Select Market LLC under the symbol "RWAYL" and "RWAYZ", respectively.

As of both March 31, 2023, and December 31, 2022, the carrying value of the Credit Facility, July 2027 Notes, August 2027 Notes, and December 2027 Notes approximates fair value. As of March 31, 2023, the fair value of the December 2026 Notes was approximately $55.1 million and the carrying value was approximately $69.2 million, net of unamortized deferred debt costs of $0.8 million. As of December 31, 2022, the fair value of the December 2026 Notes was approximately $57.0 million and the carrying value was approximately $69.2 million, net of unamortized deferred debt costs of $0.8 million.

Table of Contents

Investment Classification

The Company is a non-diversified company within the meaning of the 1940 Act. The Company classifies its investments by level of affiliation and control. As defined in the 1940 Act, investee companies are deemed as affiliated investments when a company or individual possesses, or has the right to acquire within 60 days or less, beneficial ownership of 5.0% or more of the outstanding voting securities of an investee company. Control investments are those where the investor has the ability or power to exercise a controlling influence over the management or policies of an investee company. Control is generally deemed to exist when a company or individual possesses, or has the right to acquire within 60 days or less, beneficial ownership of more than 25.0% of the outstanding voting securities of an investee company, or maintains greater than 50% representation on the investee company's board of directors.

Investments are recognized when the Company assumes an obligation to acquire a financial instrument and assumes the risks for gains or losses related to that instrument. Investments are derecognized when the Company assumes an obligation to sell a financial instrument and foregoes the risks for gains or losses related to that instrument. Specifically, the Company records all security transactions on a trade date basis. Investments in other, non-security financial instruments, such as limited partnerships or private companies, are recorded on the basis of subscription date or redemption date, as applicable. Amounts for investments recognized or derecognized but not yet settled will be reported as receivables for investments sold and payables for investments acquired, respectively, on the Statements of Assets and Liabilities.

Income Taxes

The Company elected to be treated as a RIC under Subchapter M of the Code beginning with its taxable year ended December 31, 2016, currently qualifies as a RIC, and intends to qualify annually for the tax treatment applicable to RICs. A RIC generally is not subject to U.S. federal income taxes on distributed income and gains so long as it meets certain source-of-income and asset diversification requirements and it distributes at least 90% of its net ordinary income and net short-term capital gains in excess of its net long-term capital losses, if any, to its stockholders. So long as the Company obtains and maintains its status as a RIC, it generally will not be subject to U.S. federal income tax on any ordinary income or capital gains that it distributes at least annually to its stockholders as dividends. Rather, any tax liability related to income earned by the Company represents obligations of the Company’s investors and will not be reflected in the financial statements of the Company. The Company intends to make sufficient distributions to maintain its RIC status each year and it does not anticipate paying any material U.S. federal income taxes in the future.

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward such taxable income in excess of current year dividend distributions from such current year taxable income into the next tax year and pay a 4% excise tax on such income, as required. If the Company determines that the estimated current year taxable income will exceed the estimated dividend distributions for the current year from such income, the Company accrues excise tax on estimated excess taxable income as such taxable income is earned. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with Section 946-205-45-3 of the ASC, permanent tax differences are reclassified from accumulated undistributed earnings to paid-in-capital at the end of each year and have no impact on total net assets. For more information, refer to "Note 7 – Income Taxes."

Per Share Information

Basic and diluted earnings (loss) per common share is calculated using the weighted-average number of common shares outstanding for the period presented. For the three months ended March 31, 2023 and 2022, basic and diluted earnings per share of common stock were the same because there were no potentially dilutive securities outstanding. Per share data is based on the weighted-average shares outstanding.

Table of Contents

Distributions

Distributions to common stockholders are recorded on the applicable record date. The amount, if any, to be distributed to common stockholders is determined by the Board of Directors each quarter and is generally based upon the Company's earnings estimated by management. Net realized capital gains, if any, are generally distributed at least annually.

For the three months ended March 31, 2023, the Company declared and paid dividends in the amount of $18.2 million, of which $17.5 million was distributed in cash and the remainder distributed in shares to stockholders pursuant to the Company’s Dividend Reinvestment Plan. For the three months ended March 31, 2022, the Company declared dividends in the amount of $11.2 million, of which $3.8 million was distributed in cash and the remainder distributed in shares to stockholders pursuant to the Company’s Dividend Reinvestment Plan.

Organization and Offering Costs

Organization costs include, among other things, the cost of organizing as a Maryland corporation, including the cost of legal services and other fees pertaining to the Company's organization, all of which are expensed as incurred. Offering costs include, among other things, legal fees and other costs pertaining to the preparation of the Company’s public and private offering materials as well as travel-related expenses related to the Company’s public and private offerings. Pursuant to the Advisory Agreement (as defined below), the Company and RGC agreed that organization and offering costs incurred in connection with the Initial Private Offering would be borne by the Company up to a maximum amount of $1.0 million, provided that the amount of such costs in excess of $1.0 million would be paid by RGC. As of December 31, 2016, the Company had already incurred the maximum amount of $1.0 million in organization and offering costs incurred in connection with the Initial Private Offering.

Offering costs related to the Second Private Offering were accumulated and charged to additional paid in capital at the time of closing beginning in 2019. These offering costs related to the Second Private Offering were subject to a cap of $0.6 million, excluding placement agent fees which had no cap, of which the Company will bear the cost. At the completion of the Second Private Offering, the Company had accumulated and recorded $0.7 million in offering costs and $0.2 million in placement agent fees related to the Second Private Offering. Under the terms of the Second Private Offering, offering costs in excess of $0.6 million, excluding placement agent fees, were reimbursed by RGC.

Offering costs related to the IPO were accumulated and charged to additional paid in capital at the time of closing in October 2021. The Company had accumulated and recorded $7.0 million of offering costs related to the Company’s IPO. The offering costs were fully born by the Company and included underwriting fees, legal fees, and other costs pertaining to the preparation of the Company’s offering materials as well as travel-related expenses.

Recent Accounting Pronouncements

In June 2022, the FASB issued ASU 2022-03, "Fair Value Measurement (Topic 820) - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions", which was issued to (1) clarify the guidance in Topic 820, Fair Value Measurement, when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of an equity security, (2) to amend a related illustrative example, and (3) to introduce new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value in accordance with Topic 820. The new guidance is effective for interim and annual periods beginning after December 15, 2023. The Company does not anticipate the new standard will have a material impact to the consolidated financial statements and related disclosures.

Table of Contents

Note 3 – Commitments and Contingencies

In the normal course of business, the Company may enter into investment agreements under which it commits to make an investment in a portfolio company at some future date or over a specified period of time.

As of March 31, 2023, the Company had $302.7 million in unfunded loan commitments to provide debt financing to its portfolio companies. The availability of such unfunded loan commitments is subject to the specific terms and conditions of each contract, which may include, among other things, portfolio company performance requirements and time-based cancellation provisions. As a result, only a portion of unfunded commitments is currently eligible to be drawn. The aggregate balance of unfunded commitments to extend financing as of March 31, 2023 was as follows (in thousands):


Portfolio Company	Investment Type	March 31, 2023
3PL Central LLC (dba Extensiv)	Senior Secured Term Loan	$	12,000
Brivo, Inc.	Senior Secured Term Loan		12,000
CloudPay, Inc.	Senior Secured Term Loan		15,000
Dtex Systems, Inc.	Senior Secured Term Loan		15,000
EBR Systems, Inc.	Senior Secured Term Loan		30,000
Intellisite Holdings, Inc. (dba Epic IO Technologies, Inc.)	Senior Secured Term Loan		2,000
Interactions Corporation	Senior Secured Term Loan		10,000
Kin Insurance, Inc.	Senior Secured Term Loan		25,000
Madison Reed, Inc.	Senior Secured Term Loan		2,400
Moximed, Inc.	Senior Secured Term Loan		15,000
Nalu Medical, Inc.	Senior Secured Term Loan		25,000
Revelle Aesthetics, Inc.	Senior Secured Term Loan		12,500
Route 92 Medical, Inc.	Senior Secured Term Loan		41,564
SetPoint Medical Corporation	Senior Secured Term Loan		40,000
Skillshare, Inc.	Senior Secured Term Loan		15,000
Snagajob.com, Inc.	Senior Secured Term Loan		6,785
Synack, Inc.	Senior Secured Term Loan		23,480
Total unused commitments to extend financing		$	302,729

As of December 31, 2022, the Company had $315.7 million in unfunded loan commitments to provide debt financing to its portfolio companies. The availability of such unfunded loan commitments is subject to the specific terms and conditions of each contract, which may include, among other things, portfolio company performance requirements and time-based cancellation provisions. As a result, only a portion of unfunded commitments is currently eligible to be drawn. The aggregate balance of unfunded commitments to extend financing as of December 31, 2022 was as follows (in thousands):


Portfolio Company	Investment Type	December 31, 2022
3PL Central LLC	Senior Secured Term Loan	$	15,000
Brivo, Inc.	Senior Secured Term Loan		16,000
CloudPay, Inc.	Senior Secured Term Loan		15,000
Dtex Systems, Inc.	Senior Secured Term Loan		15,000
EBR Systems, Inc.	Senior Secured Term Loan		30,000
Intellisite Holdings, Inc. (dba Epic IO Technologies, Inc.)	Senior Secured Term Loan		6,000
Interactions Corporation	Senior Secured Term Loan		10,000
Kin Insurance, Inc.	Senior Secured Term Loan		25,000
Madison Reed, Inc.	Senior Secured Term Loan		2,400
Moximed, Inc.	Senior Secured Term Loan		15,000
Nalu Medical, Inc.	Senior Secured Term Loan		25,000
Revelle Aesthetics, Inc.	Senior Secured Term Loan		12,500
Route 92 Medical, Inc.	Senior Secured Term Loan		42,000
SetPoint Medical Corporation	Senior Secured Term Loan		40,000
Skillshare, Inc.	Senior Secured Term Loan		15,000
Snagajob.com, Inc.	Senior Secured Term Loan		6,785
Synack, Inc.	Senior Secured Term Loan		25,000
Total unused commitments to extend financing		$	315,685

The Company has evaluated the expected net future cash flows related to unfunded commitments and determined the fair value to be zero as of March 31, 2023 and December 31, 2022.

The Company is currently not subject to any material legal proceedings, nor, to its knowledge, is any material proceeding threatened against the Company. From time to time, the Company may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of its rights under contracts with its portfolio companies. While the outcome of these legal proceedings cannot be predicted with certainty, the Company does not expect that any such proceedings will have a material effect upon its business, financial condition or results of operations.

Table of Contents

Other Commitments and Contingencies

On February 24, 2022, the Board of Directors approved a repurchase program (the “Repurchase Program”) under which the Company could have repurchased up to $25.0 million of its outstanding common stock. Under the Repurchase Program, the Company could have repurchased shares at management’s discretion from time to time in open-market transactions, in accordance with all applicable securities laws and regulations. As of March 31, 2023 and December 31, 2022, the Company had repurchased 871,345 shares of the Company's common stock under the Repurchase Program for an aggregate purchase price of $10.8 million. The Board of Directors did not renew the Repurchase Program, and it expired on February 24, 2023.

Note 4 – Concentration of Credit Risk

In the normal course of business, the Company maintains its cash balances in financial institutions, which at times may exceed federally insured limits. The Company is subject to credit risk to the extent that any financial institution with which it conducts business is unable to fulfill contractual obligations on its behalf. The Company monitors the financial condition of those financial institutions and does not currently anticipate any losses from these counterparties.

Note 5 – Net Increase in Net Assets Resulting from Operations per Common Share

The following information sets forth the computation of basic income per common share for the three months ended March 31, 2023 and 2022 (in thousands, except for share and per share data):


	Three Months Ended March 31,
	2023		2022
Net increase in net assets resulting from operations	$	11,984	$	2,853
Weighted average shares outstanding for the period
Basic		40,509,269		41,375,187
Diluted		40,509,269		41,375,187
Per Share Data(1):
Basic and diluted income (loss) per common share
Basic	$	0.30	$	0.07
Diluted	$	0.30	$	0.07

(1)

Per share data is based on average weighted shares outstanding.

Table of Contents

Note 6 – Net Assets

The Company has the authority to issue 100,000,000 shares of common stock, $0.01 par value per share. In October 2015, in connection with the Company's formation, the Company issued and sold 1,667 shares of common stock to R. David Spreng, the President and Chief Executive Officer of the Company and Chairman of the Company's Board of Directors, for an aggregate purchase price of $25 thousand.

Private Common Stock Offerings

On December 1, 2017, the Company completed its initial private offering ("Initial Private Offering"), in which the Company issued 18,241,157 shares of its common stock to stockholders for a total purchase price of $275.0 million in reliance on exemptions from the registration requirements of the Securities Act, and other applicable securities laws.

Beginning October 15, 2019 and ending September 29, 2021, the Company had completed multiple closings under its second private offering (the "Second Private Offering") and had accepted aggregate capital commitments of $181.7 million. In connection with the Second Private Offering the Company has issued 9,617,379 shares of its common stock for a total purchase price of $144.3 million. Concurrent with the IPO (as defined below), all undrawn commitments under the Second Private Offering were cancelled.

On March 31, 2020 and March 24, 2021, the Company had issued in aggregate 22,564 shares as an additional direct investment by Runway Growth Holdings LLC, an affiliate of RGC, at a per-share price of $15.00 for total proceeds of $0.3 million in a private offering pursuant to an exemption from registration under Regulation D of the Securities Act.

Initial Public Offering

The Company closed its initial public offering ("IPO"), issuing 6,850,000 shares of its common stock at a public offering price of $14.60 per share. Net of underwriting fees and offering costs, the Company received net cash proceeds of $93.0 million. The Company’s common stock began trading on the Nasdaq Global Select Market LLC on October 21, 2021 under the symbol “RWAY”.

Distribution Reinvestment Plan

The Company maintains a dividend reinvestment plan for common stockholders (the "Dividend Reinvestment Plan"). The Company's Dividend Reinvestment Plan is administered by its transfer agent on behalf of the Company's record holders and participating brokerage firms. Brokerage firms and other financial intermediaries may decide not to participate in the Company's Dividend Reinvestment Plan but may provide a similar distribution reinvestment plan for their clients. The share requirements of the Dividend Reinvestment Plan may be satisfied through the issuance of new common shares or through open market purchases of common shares by the Company.

During the three months ended March 31, 2023, the Company did not purchase any shares of common stock in the open market under the Dividend Reinvestment Plan. During the three months ended March 31, 2022, the Company purchased 31,782 shares of common stock in the open market for a total of $0.4 million under the Dividend Reinvestment Plan.

Table of Contents

Repurchase Program

The following table summarized the distributions declared and paid since inception through March 31, 2023:


Declaration Date	Record Date	Payment Date	Amount per Share
May 3, 2018	May 15, 2018	May 31, 2018	$	0.15
July 26, 2018	August 15, 2018	August 31, 2018	$	0.25
November 1, 2018	October 31, 2018	November 15, 2018	$	0.35
March 22, 2019	March 22, 2019	March 26, 2019	$	0.40
May 2, 2019	May 7, 2019	May 21, 2019	$	0.45
May 2, 2019	May 31, 2019	July 16, 2019	$	0.46
July 30, 2019	August 5, 2019	August 26, 2019	$	0.45
September 27, 2019	September 30, 2019	November 12, 2019	$	0.04
December 9, 2019	December 10, 2019	December 23, 2019	$	0.40
March 5, 2020	March 6, 2020	March 20, 2020	$	0.40
May 7, 2020	May 8, 2020	May 21, 2020	$	0.35
August 5, 2020	August 6, 2020	August 20, 2020	$	0.36
October 1, 2020	October 1, 2020	November 12, 2020	$	0.38
March 4, 2021	March 5, 2021	March 19, 2021	$	0.37
April 29, 2021	April 30, 2021	May 13, 2021	$	0.37
July 19, 2021	July 20, 2021	August 12, 2021	$	0.34
October 28, 2021	November 8, 2021	November 22, 2021	$	0.25
February 24, 2022	March 8, 2022	March 22, 2022	$	0.27
April 28, 2022	May 10, 2022	May 24, 2022	$	0.30
July 28, 2022	August 9, 2022	August 23, 2022	$	0.33
October 27, 2022	November 8, 2022	November 22, 2022	$	0.36
February 23, 2023	March 7, 2023	March 21, 2023	$	0.45

Table of Contents

Note 7 – Income Taxes

The Company elected to be treated as a RIC under Subchapter M of the Code starting with its taxable year ended December 31, 2016. The Company currently qualifies and intends to qualify annually for the tax treatment applicable to RICs. A RIC generally is not subject to U.S. federal income taxes on distributed income and gains so long as it meets certain source-of-income and asset diversification requirements and it distributes at least 90% of its net ordinary income and net short-term capital gains in excess of its net long-term capital losses, if any, to its stockholders. So long as the Company obtains and maintains its status as a RIC, it generally will not be subject to U.S. federal income tax on any ordinary income or capital gains that it distributes at least annually to its stockholders as dividends. Rather, any tax liability related to income earned by the Company represents obligations of the Company’s investors and will not be reflected in the financial statements of the Company. The Company intends to make sufficient distributions to maintain its RIC status each year and it does not anticipate paying any material United States federal income taxes in the future.

Federal income tax regulations differ from U.S. GAAP, therefore distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary in nature. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.

The following table sets forth the tax cost basis and the estimated aggregate gross unrealized appreciation and depreciation on investments for federal income tax purposes as of and for the period ended March 31, 2023 and the year ended December 31, 2022 (in thousands):


	March 31, 2023			December 31, 2022
	(Unaudited)
Tax cost on investments	$	1,186,455		$	1,149,902
Change in unrealized appreciation on a tax basis	$	11,271		$	9,207
Change in unrealized depreciation on a tax basis		(37,410	)		(32,800	)
Net unrealized appreciation (depreciation) on a tax basis	$	(26,139	)	$	(23,593	)

The Company accounts for income taxes in conformity with ASC Topic 740 — Income Taxes ("ASC 740"). ASC 740 provides guidelines for how uncertain tax positions should be recognized, measured, presented and disclosed in Consolidated Financial Statements. ASC 740 requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more-likely-than-not" of being sustained by the applicable tax authority. Tax positions deemed to meet a "more-likely-than-not" threshold would be recorded as a tax benefit or expense in the current period. The Company recognizes interest and penalties, if any, related to unrecognized tax benefits as income tax expense in the Statements of Operations. There were no material uncertain income tax positions at March 31, 2023 or December 31, 2022. Although the Company files federal and state tax returns, the Company's major tax jurisdiction is federal. The previous three tax year-ends and the interim tax period since then remain subject to examination by the Internal Revenue Service.

If the Company does not distribute (or is not deemed to have distributed) each calendar year the sum of (1) 98% of its net ordinary income for each calendar year, (2) 98.2% of its capital gain net income for the one-year period ending October 31 in that calendar year and (3) any income recognized, but not distributed, in preceding years (the “Minimum Distribution Amount”), the Company will generally be required to pay a U.S. federal excise tax equal to 4% of the amount by which the Minimum Distribution Amount exceeds the distributions for the year. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year dividend distributions from such taxable income, the Company accrues excise taxes, if any, on estimated excess taxable income as taxable income is earned using an annual effective excise tax rate. The annual effective U.S. federal excise tax rate is determined by dividing the estimated annual excise tax by the estimated annual taxable income.

If the Company does not qualify to be treated as a RIC for any taxable year, the Company will be taxed as a regular corporation (a “C corporation”) under subchapter C of the Code for such taxable year. If the Company has previously qualified as a RIC but is subsequently unable to qualify, and certain amelioration provisions are not applicable, the Company would be subject to U.S. federal income tax on all of its taxable income (including its net capital gains) at regular corporate rates. The Company would not be able to deduct distributions to stockholders, nor would it be required to make distributions. In order to requalify as a RIC, in addition to the other requirements discussed above, the Company would be required to distribute all of its previously undistributed earnings attributable to the period it failed to qualify by the end of the first year that it intends to requalify. If the Company fails to requalify for a period greater than two taxable years, it may be subject to U.S. federal income tax at corporate tax rates on any net built-in gains with respect to certain of its assets (i.e., the excess of the aggregate gains, including items of income, over aggregate losses that would have been realized with respect to such assets if the Company had been liquidated) that it elects to recognize on requalification or when recognized over the next five years.

Table of Contents

Note 8 – Related Party Agreements and Transactions

Second Amended and Restated Advisory Agreement

On November 29, 2016, the Company’s Board of Directors approved an investment advisory agreement between RGC and the Company, under which RGC, subject to the overall supervision of the Board of Directors, manages the day-to-day operations of and provides investment advisory services to the Company (together with a subsequent amendment thereto, the “Prior Advisory Agreement”). On August 3, 2017, the Board of Directors approved certain amendments to the Prior Advisory Agreement (the “First Amended and Restated Advisory Agreement”) and recommended that the Company’s stockholders approve the First Amended and Restated Advisory Agreement. The First Amended and Restated Advisory Agreement became effective on September 12, 2017 upon approval by the stockholders at a special meeting of stockholders of the Company. On April 7, 2021, the Board of Directors approved certain additional amendments to the advisory agreement (the “Advisory Agreement”) at a virtual meeting and recommended that the Company’s stockholders approve the Advisory Agreement. In reliance upon certain exemptive relief granted by the SEC in connection with the global COVID-19 pandemic, the Board of Directors undertook to ratify the Advisory Agreement at its next in-person meeting which was held in July 2021. The Advisory Agreement became effective on May 27, 2021 upon approval by the stockholders at a special meeting of stockholders of the Company. The Advisory Agreement amended the Prior Advisory Agreement to include certain revisions to the management and incentive fee calculation mechanisms and clarify language relating to liquidity events. Under the terms of the Advisory Agreement, RGC:

•

determines the composition of the Company’s portfolio, the nature and timing of the changes to the portfolio and the manner of implementing such changes;

•

identifies, evaluates and negotiates the structure of the investments the Company makes;

•

executes, closes and monitors the investments the Company makes;

•

determines the securities and other assets that the Company will purchase, retain or sell;

•

performs due diligence on prospective investments; and

•

provides the Company with other such investment advisory, research and related services as the Company may, from time to time, reasonably require for the investment of its funds.

Pursuant to the Advisory Agreement, the Company pays RGC a fee for its investment advisory and management services consisting of two components – a base management fee and an incentive fee. The cost of both the base management fee and incentive fee are ultimately borne by the Company’s stockholders.

Base Management Fee

The base management fee is payable on the first day of each calendar quarter.

For purposes of the Advisory Agreement, a “Spin-Off transaction” includes either a transaction whereby (a) the Company offers its stockholders the option to elect to either (i) retain their ownership of shares of the Company’s common stock, or (ii) exchange their shares of the Company’s common stock for shares of common stock in a newly formed entity (the “Public Fund”) that will elect to be regulated as a BDC under the 1940 Act and treated as a RIC under Subchapter M of the Code (the “Public Fund Spin Off”); or (b) the Company completes a listing of the Company’s securities on any securities exchange (an “Exchange Listing”). The base management fee will be an amount equal to 0.40% (1.60% annualized) of the Company’s average daily Gross Assets (defined below) during the most recently completed calendar quarter for so long as the aggregate amount of Gross Assets of the Company as of the end of the most recently completed calendar quarter is equal or greater than $500 million but less than $1.0 billion. For purposes of the Advisory Agreement, “Gross Assets” is defined as the Company’s gross assets, including assets purchased with borrowed funds or other forms of leverage, as well as any PIK interest, as of the end of the most recently completed fiscal quarter. If the aggregate amount of the Company’s Gross Assets as of the end of the most recently completed calendar quarter is less than $500 million the base management fee will be an amount equal to 0.4375% (1.75% annualized) of the Company’s average daily Gross Assets during the most recently completed calendar quarter. If the aggregate amount of the Company’s Gross Assets as of the end of the most recently completed calendar quarter is equal to or greater than $1.0 billion, the base management fee will be an amount equal to 0.375% (1.50% annualized) of the Company’s average daily Gross Assets during the most recently completed calendar quarter.

RGC earned base management fees of $4.0 million for the three months ended March 31, 2023, and $2.6 million for the three months ended March 31, 2022.

Table of Contents

Incentive Fee

The incentive fee, which provides RGC with a share of the income that RGC generates for the Company, consists of an investment-income component and a capital-gains component, which are largely independent of each other, with the result that one component may be payable even if the other is not.

Under the investment-income component (the “Income Incentive Fee”), the Company pays RGC each quarter an incentive fee with respect to the Company’s Pre-Incentive Fee net investment income. The Income Incentive Fee is calculated and payable quarterly in arrears based on the Pre-Incentive Fee net investment income for the immediately preceding fiscal quarter. Payments based on Pre-Incentive Fee net investment income will be based on the Pre-Incentive Fee net investment income earned for the quarter. For this purpose, “Pre-Incentive Fee net investment income” means interest income, dividend income and any other income (including any other fees, such as commitment, origination, structuring, diligence, managerial and consulting fees or other fees that the Company receives from portfolio companies) that the Company accrues during the fiscal quarter, minus the Company’s operating expenses for the quarter (including the base management fee, expenses payable under the amended and restated administration agreement with the Administrator (the “Administration Agreement”), and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-Incentive Fee net investment income includes, in the case of investments with a deferred interest feature (such as OID accretion, debt instruments with pay in kind interest and zero coupon securities), accrued income the Company has not yet received in cash; provided, however, that the portion of the Income Incentive Fee attributable to deferred interest features will be paid, only if and to the extent received in cash, and any accrual thereof will be reversed if and to the extent such interest is reversed in connection with any write off or similar treatment of the investment giving rise to any deferred interest accrual, applied in each case in the order such interest was accrued. Such subsequent payments in respect of previously accrued income will not reduce the amounts payable for any quarter pursuant to the calculation of the Income Incentive Fee described above. Pre-Incentive Fee net investment income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation.

Pre-Incentive Fee net investment income, expressed as a rate of return on the value of the Company’s net assets (defined as total assets less liabilities) at the end of the immediately preceding fiscal quarter, will be compared to a “hurdle rate” of 2.0% per quarter (8.0% annualized). The Company pays RGC an Income Incentive Fee with respect to the Company’s Pre-Incentive Fee net investment income in each calendar quarter as follows: (1) no Income Incentive Fee in any calendar quarter in which the Company’s Pre-Incentive Fee net investment income does not exceed the hurdle rate of 2.0%; (2) 80% of the Company’s Pre-Incentive Fee net investment income with respect to that portion of such Pre-Incentive Fee net investment income, if any, that exceeds the hurdle rate but is less than 2.667% in any calendar quarter (10.668% annualized) (the portion of the Company’s Pre-Incentive Fee net investment income that exceeds the hurdle but is less than 2.667% is referred to as the “catch-up” the “catch-up” is meant to provide RGC with 20.0% of the Company’s Pre-Incentive Fee net investment income as if a hurdle did not apply if the Company’s Pre-Incentive Fee net investment income exceeds 2.667% in any calendar quarter (10.668% annualized)); and (3) 20.0% of the amount of the Company’s Pre-Incentive Fee net investment income, if any, that exceeds 2.667% in any calendar quarter (10.668% annualized) payable to RGC (once the hurdle is reached and the catch-up is achieved, 20.0% of all Pre-Incentive Fee net investment income thereafter is allocated to RGC).

Until the consummation of a Spin-Off transaction, in the event that (a) the sum of the Company’s cumulative net realized losses since the date of the Company’s election to be regulated as a BDC exceeded 2.0% of the total non-control/non-affiliate investments made by the Company since the date of the Company’s election to be regulated as a BDC through the end of the quarter and (b) the Pre-Incentive Fee net investment income adjusted to include any realized capital gains and losses (“Adjusted Pre-Incentive Fee net investment income”), expressed as an annualized rate of return on the value of the Company’s average daily net assets (defined as total assets less liabilities), since the Company’s election to be regulated as a BDC through the end of the quarter was less than 10.0%, no Income Incentive Fee would be payable for such quarter until the first subsequent quarter in which either (x) the sum of the Company’s cumulative net realized losses since the date of the Company’s election to be regulated as a BDC was equal to or less than 2.0% of the total non-control/non-affiliate investments made by the Company since the date of the Company’s election to be regulated as a BDC through the end of such subsequent quarter or (y) the Adjusted Pre-Incentive Fee net investment income, expressed as an annualized rate of return on the value of the Company’s average daily net assets (defined as total assets less liabilities), since the Company’s election to be regulated as a BDC through the of the end of the quarter equals or exceeds 10.0%; provided, however, that in no event would any Income Incentive Fee be payable for any prior quarter after the three-year anniversary of the end of such quarter.

Under the capital gains component of the incentive fee (the “Capital Gains Fee”), the Company will pay RGC, as of the end of each calendar year, 20.0% of the Company’s aggregate cumulative realized capital gains, if any, from the date of the Company’s election to be regulated as a BDC through the end of that calendar year, computed net of the Company’s aggregate cumulative realized capital losses and aggregate cumulative unrealized capital depreciation through the end of such year, less the aggregate amount of any previously paid Capital Gains Fee. For the foregoing purpose, the Company’s “aggregate cumulative realized capital gains” will not include any unrealized appreciation. If such amount is negative, then no Capital Gains Fee will be payable for such year.

Table of Contents

For the three months ended March 31, 2023, RGC earned incentive fees of $4.6 million; $3.5 million of which was payable in cash and $1.1 million were accrued and generated from deferred interest. For the three months ended March 31, 2022, RGC earned incentive fees of $1.3 million; $1.1 million of which was payable in cash and $0.3 million were accrued and generated from deferred interest. All incentive fees accrued and generated from deferred interest (i.e., PIK and certain discount accretion) are not payable until receipt of respective cash by the Company. As of March 31, 2023, $3.7 million were payable in cash, and $5.9 million were deferred incentive fees payable, both of which are included in incentive fees payable on the Statements of Assets and Liabilities. As of December 31, 2022, $3.8 million were payable in cash, and $5.0 million were deferred incentive fees payable, both of which are included in incentive fees payable on the Statements of Assets and Liabilities.

The capital gains incentive fee consists of fees related to realized gains, realized capital losses and unrealized capital depreciation. With respect to the incentive fee expense accrual related to the capital gains incentive fee, U.S. GAAP requires that the capital gains invective fee accrual consider the cumulative aggregate unrealized appreciation in the calculation, as a capital gains incentive fee would be payable if such unrealized appreciation were realized even though such unrealized appreciation is not permitted to be considered in calculating the fee actually payable under the Advisory Agreement. As of each of March 31, 2023 and December 31, 2022, there was no capital gains incentive fee accrued, earned or payable to RGC under the Advisory Agreement.

Spin-Off Incentive Fee

The Income Incentive Fee will be payable in connection with a Public Fund Spin-Off as follows. The Income Incentive Fee will be calculated as of the date of the completion of each Public Fund Spin-Off and will equal the amount of Income Incentive Fee that would be payable to RGC if (1) all of the Company’s investments were liquidated for their current value and any unamortized deferred portfolio investment-related fees would be deemed accelerated, (2) the proceeds from such liquidation were used to pay all of the Company’s outstanding liabilities, and (3) the remainder were distributed to the Company’s stockholders and paid as incentive fee in accordance with the Income Incentive Fee described in clauses (1) and (2) above for determining the amount of the Income Incentive Fee; provided, however, that in no event will the Income Incentive Fee paid in connection with the completion of the Public Fund Spin-Off (x) include the portion of the Income Incentive Fee attributable to deferred interest features of a particular investment that is not transferred pursuant to the Public Fund Spin-Off until such time as the deferred interest is received in cash, or (y) exceed 20.0% of the Company’s Pre-Incentive Fee net investment income accrued by the Company for the fiscal quarter as of the date of the completion of the Public-Fund Spin-Off. The Company will make the payment of the Income Incentive Fee paid in connection with the completion of the Public Fund Spin-Off in cash on or immediately following the date of the completion of the Public-Fund Spin-Off. After the Public Fund Spin-Off, all calculations relating to the incentive fee payable will be made beginning on the day immediately following the completion of the Public Fund Spin-Off without taking into account the exchanged shares of the Company’s common stock (or contributions, distributions or proceeds relating thereto).

The Capital Gains Fee will be payable in respect of the exchanged shares of the Company’s common stock in connection with the Public Fund Spin-Off and will be calculated as of the date of the completion of the Public Fund Spin-Off as if such date were a calendar year-end for purposes of calculating and paying the Capital Gains Fee.

No Income Incentive Fee or Capital Gains Fee will be payable in connection with the Public Fund Spin-Off unless, on the date of the completion of the Public Fund Spin-Off, the sum of the Company’s (i) Pre-Incentive Fee net investment income and (ii) realized capital gains less realized capital losses and unrealized capital depreciation from the date of the Company’s election to be regulated as a BDC through, and including, the date of the completion of the Public Fund Spin-Off, is greater than 8.0% of the cumulative net investments made by the Company since the Company’s election to be regulated as a BDC.

Table of Contents

Administration Agreement

The Company reimburses the Administrator for the allocable portion of overhead and other expenses incurred by the Administrator in performing its obligations under the Administration Agreement, including furnishing the Company with office facilities, equipment and clerical, bookkeeping and recordkeeping services at such facilities, as well as providing other administrative services. In addition, the Company reimburses the Administrator for the fees and expenses associated with performing compliance functions, and the Company’s allocable portion of the compensation of certain of its officers, including the Company’s Chief Financial Officer, Chief Compliance Officer and any administrative support staff.

The Company reimbursed the Administrator $0.4 million during the three months ended March 31, 2023. As of March 31, 2023, the Company had accrued a net payable to the Administrator of $0.7 million, which is included in Accrued expenses and other on the Statement of Assets and Liabilities. Of the total amount reimbursed to the Administrator, $0.4 million was related to overhead allocation expense during the three months ended March 31, 2023. The Company reimbursed the Administrator $0.3 million during the three months ended March 31, 2022. As of March 31, 2022, the Company accrued a net payable to the Administrator of $0.2 million. Of the total amount reimbursed to the Administrator, $0.3 million was related to overhead allocation expense for the three months ended March 31, 2022. As of December 31, 2022, the Company had accrued a net payable to the Administrator of $0.4 million. Administration fees, which include fees payable by the Administrator to third-party service providers who provide additional administration services for the Company, were $0.2 million for the three months ended March 31, 2023. Administration fees, which include fees payable by the Administrator to third-party service providers who provide additional administration services for the Company, were $0.2 million for the three months ended March 31, 2022.

License Agreement

The Company has entered into a license agreement with RGC (the “License Agreement”) pursuant to which RGC has granted the Company a personal, non-exclusive, royalty-free right and license to use the name “Runway Growth Finance.” Under the License Agreement, the Company has the right to use the “Runway Growth Finance” name for so long as RGC or one of its affiliates remains the Company’s investment adviser. Other than with respect to this limited license, the Company has no legal right to the “Runway Growth Finance” name.

Strategic Relationship

In December 2016, the Company and RGC entered into a strategic relationship with Oaktree Capital Management, L.P (“Oaktree”). In connection, OCM Growth Holdings ("OCM") purchased an aggregate of 14,571,334 shares of the Company's common stock for an aggregate purchase price of $219.3 million in the Company's Initial Private Offering and Second Private Offering. As of March 31, 2023, OCM owns 21,129,668 shares of the Company's common stock or approximately 52% of the Company's outstanding shares. Pursuant to an irrevocable proxy, the shares held by OCM must be voted in the same proportion that the Company's other stockholders vote their shares.

In connection with OCM’s commitment, the Company entered into a stockholder agreement, dated December 15, 2016, with OCM, pursuant to which OCM has a right to nominate a member of the Company’s Board of Directors for election for so long as OCM holds shares of the Company’s common stock in an amount equal to, in the aggregate, at least one-third (33%) of OCM’s initial $125.0 million capital commitment. Brian Laibow, Co-Head of Oaktree's North America & Managing Director Opportunities Funds, serves on the Company’s Board of Directors as OCM’s director nominee and is considered an interested director. OCM also holds a minority interest in RGC and has the right to appoint a member of RGC’s board of managers and a member of RGC’s investment committee. Brian Laibow is OCM’s appointee to RGC’s board of managers and investment committee.

Table of Contents

Note 9 – Fair Value Measurements

The Company’s assets recorded at fair value have been categorized based upon a fair value hierarchy in accordance with ASC Topic 820. Refer to "Note 2 — Summary of Significant Accounting Policies" for a discussion of the Company’s policies.

Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of March 31, 2023 and December 31, 2022 (in thousands):


	As of March 31, 2023
	Level 1		Level 2		Level 3		Total
Portfolio Investments
Preferred Stock	$	12,785	$	—	$	22,099	$	34,884
Common Stock		1,044		—		921		1,965
Senior Secured Term Loans		—		—		1,060,495		1,060,495
Second Lien Term Loans		—		—		13,707		13,707
Warrants		—		79		14,212		14,291
Total Portfolio Investments		13,829		79		1,111,434		1,125,342
U.S. Treasury Bill		34,974		—		—		34,974
Total Investments	$	48,803	$	79	$	1,111,434	$	1,160,316


	As of December 31, 2022
	Level 1		Level 2		Level 3		Total
Portfolio Investments
Preferred Stock	$	12,335	$	—	$	347	$	12,682
Common Stock		501		1,422		1,174		3,097
Senior Secured Term Loans		—		—		1,080,121		1,080,121
Second Lien Term Loans		—		—		13,654		13,654
Warrants		—		105		16,650		16,755
Total Portfolio Investments		12,836		1,527		1,111,946		1,126,309
U.S. Treasury Bill		—		—		—		—
Total Investments	$	12,836	$	1,527	$	1,111,946	$	1,126,309

The Company transfers investments in and out of Levels 1, 2 and 3 as of the beginning balance sheet date, based on changes in the use of observable and unobservable inputs utilized to perform the valuation for the period.

Table of Contents

The following table presents a rollforward of Level 3 assets measured at fair value as of March 31, 2023 (in thousands):


	Preferred Stock			Common Stock			Senior Secured Term Loans			Second Lien Term Loans			Warrants			Total
Fair value at December 31, 2022	$	347		$	1,174		$	1,080,121		$	13,654		$	16,650		$	1,111,946
Transfers out of Level 3		—			—			—			—			—			—
Purchases of investments(1)		25,000			—			(12,505	)		—			376			12,871
PIK interest		—			—			3,584			171			—			3,755
Sales or repayments of investments(1)		—			—			(14,199	)		—			—			(14,199	)
Realized gain (loss)		—			—			—			—			(1,178	)		(1,178	)
Change in unrealized appreciation (depreciation)		(3,248	)		(253	)		658			(146	)		(1,636	)		(4,625	)
Amortization of fixed income premiums or accretion of discounts		—			—			2,836			28			—			2,864
Fair value at March 31, 2023	$	22,099		$	921		$	1,060,495		$	13,707		$	14,212		$	1,111,434
Change in unrealized appreciation (depreciation) on Level 3 investments still held as of March 31, 2023	$	(3,248	)	$	(253	)	$	865		$	(146	)	$	(2,930	)	$	(5,712	)

(1)

Net of reorganization and restructuring of investments.

The following table presents a rollforward of Level 3 assets measured at fair value as of March 31, 2022 (in thousands):


	Preferred Stock		Common Stock			Senior Secured Term Loans			Second Lien Term Loans		Warrants			Total
Fair value at December 31, 2021	$	1,332	$	—		$	623,054		$	12,873	$	20,087		$	657,346
Transfers out of Level 3		—		—			—			—		—			—
Purchases of investments(1)		—		4,551			80,371			—		598			85,520
PIK interest		—		—			1,187			150		—			1,337
Sales or repayments of investments(1)		—		—			(7,987	)		—		(262	)		(8,249	)
Realized gain (loss)		—		—			—			—		(267	)		(267	)
Change in unrealized appreciation (depreciation)		109		(3,202	)		(848	)		—		1,179			(2,762	)
Amortization of fixed income premiums or accretion of discounts		—		—			2,799			26		—			2,825
Fair Value at March 31, 2022	$	1,441	$	1,349		$	698,576		$	13,049	$	21,335		$	735,750
Change in unrealized appreciation (depreciation) on Level 3 investments still held as of March 31, 2022	$	109	$	(3,202	)	$	(2,651	)	$	—	$	858		$	(4,886	)

(1)

Net of reorganization and restructuring of investments.

Table of Contents

The following table provides quantitative information regarding Level 3 fair value measurements as of March 31, 2023 (in thousands):


Description	Fair Value		Valuation Technique	Unobservable Inputs	Range (Weighted Average)
Preferred Stock	$	278	Recent private market and merger and acquisition transaction prices	N/A	N/A
		21,821	PWERM	Discount rate	28.0% - 28.0% (28.0%)
Common Stock		921	Recent private market and merger and acquisition transaction prices	N/A	N/A
Senior Secured Term Loans(1)		1,031,181	Discounted Cash Flow analysis	Discount rate	11.5% - 24.9% (15.5%)
			Market approach	Origination yield	10.5% - 16.6% (13.1%)
		29,314	PWERM	Discount rate	30.0% - 39.7% (35.9%)
Second Lien Term Loans (1)		13,707	Discounted Cash Flow analysis	Discount rate	16.8% - 16.8% (16.8%)
			Market approach	Origination yield	14.8% - 14.8% (14.8%)
Warrants(2)		9,859	Option pricing model	Risk-free interest rate	3.7% - 5.2% (4.6%)
				Average industry volatility	30.0% - 97.2% (51.8%)
				Estimated time to exit	0.5 - 5.0 (2.6 years)
				Revenue multiples	1.14x - 45.10x (3.77x)
		4,353	PWERM	Discount rate	20.0% - 40.0% (33.7%)
				Revenue multiples	2.32x - 198.68x (17.65x)
Total Level 3 Investments	$	1,111,434

The following table provides quantitative information regarding Level 3 fair value measurements as of December 31, 2022 (in thousands):


Description	Fair Value		Valuation Technique	Unobservable Inputs	Range (Weighted Average)
Preferred Stock	$	347	Recent private market and merger and acquisition transaction prices	N/A	N/A
Common Stock		1,174	Recent private market and merger and acquisition transaction prices	N/A	N/A
Senior Secured Term Loans(1)		1,053,748	Discounted Cash Flow analysis	Discount rate	11.1% - 28.0% (15.2%)
			Market approach	Origination yield	10.5% - 19.3% (12.9%)
		26,373	PWERM	Discount rate	27.4% - 37.4% (30.9%)
Second Lien Term Loans (1)		13,654	Discounted Cash Flow analysis	Discount rate	16.1% - 16.1% (16.1%)
			Market approach	Origination yield	12.2% - 12.2% (12.2%)
Warrants(2)		10,246	Option pricing model	Risk-free interest rate	2.7% - 4.9% (4.3%)
				Average industry volatility	25.0% - 98.4% (49.0%)
				Estimated time to exit	0.5 - 5.0 (2.2 years)
				Revenue multiples	1.16x - 88.63x (5.47x)
		6,404	PWERM	Discount rate	20.0% - 40.0% (34.6%)
				Revenue multiples	2.35x - 199.38x (13.10x)
Total Level 3 Investments	$	1,111,946

(1)

The significant unobservable inputs used in the fair value measurement of the Company’s debt securities are origination yields and discount rates. The origination yield is defined as the initial market price of an investment in a hypothetical market to hypothetical market participants where buyers and sellers are willing participants. The discount rate is related to company-specific characteristics such as underlying investment performance, projected cash flows, and other characteristics of the investment. Significant increases (decreases) in the inputs in isolation may result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. However, a significantly higher or lower fair value measurement of any of the Company’s portfolio investments may occur regardless of whether there is a significant increase (decrease) in the unobservable inputs.

(2)

The significant unobservable inputs used in the fair value measurement of the Company’s warrant and equity-related securities are inputs used in the OPM, which include industry volatility, risk free interest rate and estimated time to exit. The Equity Allocation model and the Black Scholes model were the main OPMs used during the period ended March 31, 2023 and the year ended December 31, 2022. Probability Weighted Expected Return Models (“PWERM”) and other techniques were used as determined appropriate. Significant increases (decreases) in the inputs in isolation would result in a significantly higher (lower) fair value measurement, depending on the materiality of the investment. However, a significantly higher or lower fair value measurement of any of the Company’s portfolio investments may occur regardless of whether there is a significant increase (decrease) in the unobservable inputs. For some investments, additional consideration may be given to data from the last round of financing or merger/acquisition events near the measurement date.

Table of Contents

Note 10 – Derivative Financial Instruments

In the normal course of business, the Company may utilize derivative contracts in connection with its investment activities. Investments in derivative contracts are subject to additional risks that can result in a loss of all or part of an investment. The derivative activities and exposure to derivative contracts primarily involve equity price risks. In addition to the primary underlying risk, additional counterparty risk exists due to the potential inability of counterparties to meet the terms of their contracts.

Warrants

Warrants provide exposure and potential gains upon equity appreciation of the portfolio company’s equity value. A warrant has a limited life and expires on a certain date. As a warrant’s expiration date approaches, the time value of the warrant will decline. In addition, if the stock underlying the warrant declines in price, the intrinsic value of an “in the money” warrant will decline. Further, if the price of the stock underlying the warrant does not exceed the strike price of the warrant on the expiration date, the warrant will expire worthless. As a result, there is the potential for the entire value of an investment in a warrant to be lost. The Company’s volume of warrant investment activity is closely correlated to its primary senior secured loans to portfolio companies. For the three months ended March 31, 2023, the Company had realized losses of $1.2 million, and a net unrealized depreciation of $1.7 million from its investments in warrants. For the three months ended March 31, 2022, the Company had realized losses of $0.3 million and a net unrealized appreciation of $1.2 million from its investments in warrants. Realized gains(losses) from warrants are included in the respective control, affiliate, or non-control/non-affiliate Realized gain/(loss) on investments on the Statement of Operations. Net change in unrealized appreciation/(depreciation) from investments in warrants is included in the respective control, affiliate, or non-control/non-affiliate Net change in unrealized appreciation (depreciation) on investments on the Statement of Operations.

Counterparty risk exists from the potential failure of an issuer of warrants to settle its exercised warrants. The maximum risk of loss from counterparty risk is the fair value of the contracts and the purchase price of the warrants. The Company’s Board of Directors considers the effects of counterparty risk when determining the fair value of its investments in warrants.

Table of Contents

Note 11 – Borrowings

The following table shows the Company's borrowings as of March 31, 2023 and December 31, 2022 (in thousands):


	March 31, 2023									December 31, 2022
	Total Commitment		Principal		Deferred Debt Cost(1)			Carrying Value		Total Commitment		Principal		Deferred Debt Cost(1)			Carrying Value
Credit Facility	$	500,000	$	372,000	$	(4,968	)	$	367,032	$	425,000	$	337,000	$	(4,640	)	$	332,360
December 2026 Notes		70,000		70,000		(766	)		69,234		70,000		70,000		(818	)		69,182
July 2027 Notes		80,500		80,500		(2,251	)		78,249		80,500		80,500		(2,380	)		78,120
August 2027 Notes		20,000		20,000		(618	)		19,382		20,000		20,000		(653	)		19,347
December 2027 Notes		51,750		51,750		(1,724	)		50,026		51,750		51,750		(1,802	)		49,948
Total	$	722,250	$	594,250	$	(10,327	)	$	583,923	$	647,250	$	559,250	$	(10,293	)	$	548,957

(1) Net of accumulated amortization.

For the three months ended March 31, 2023 and 2022, the components of interest expense, amortization of deferred debt costs, and the unused fees on the Credit Facility (as defined below) on the Company's borrowings were as follows (dollars in thousands):


	Interest Expense		Amortization of Deferred Debt Costs		Unused Facility and Other Fees (1)		Total Interest and Other Debt Financing Expenses		Weighted Average Cost of Debt

Three Months Ended March 31, 2023
Credit Facility	$	6,409	$	394	$	172	$	6,975		8.37	%
December 2026 Notes		744		52		—		796		4.55	%
July 2027 Notes		1,509		129		—		1,638		8.14	%
August 2027 Notes		350		35		—		385		7.70	%
December 2027 Notes		1,035		91		—		1,126		8.71	%
Total, 2023	$	10,047	$	701	$	172	$	10,920

Three Months Ended March 31, 2022
Credit Facility	$	364	$	118	$	555	$	1,037		9.96	%
December 2026 Notes		508		34		—		542		4.54	%
Total, 2022	$	872	$	152	$	555	$	1,579

(1)

Unused facility and other fees for the three months ended March 31, 2022 include supplemental fees of $0.2 million, which were incurred through the first half of 2022 and were nonrecurring in nature.

Table of Contents

Credit Facility

On May 31, 2019, the Company entered into a Credit Agreement with KeyBank National Association, acting as administrative agent and syndication agent and the other lenders party thereto, which initially provided the Company with a $100.0 million commitment, subject to borrowing base requirements (as amended and restated from time to time, the “Credit Facility”). As of March 31, 2023, the Company had $500.0 million in total commitments available under the Credit Facility. The availability period under the Credit Facility expires on April 20, 2025 and is followed by a one-year amortization period. The stated maturity date under the Credit Facility is April 20, 2026, unless extended.

Borrowings under the Credit Facility bear interest on a per annum rate equal to the Adjusted Term Secured Overnight Financing Rate (“SOFR”) plus an applicable margin rate that ranges from 2.95% to 3.35% per annum depending on the Company’s leverage ratio and number of eligible loans in the collateral pool. The Credit Facility provides for a variable advance rate of up to 65% on eligible term loans. The Company also pays an unused commitment fee that ranges from 0.25% to 1.00% per annum based on the total unused lender commitments under the Credit Facility.

The Credit Facility is collateralized by all eligible investment assets held by the Company. The Credit Facility contains representations and warranties and affirmative and negative covenants customary for secured financings of this type, including certain financial covenants such as a consolidated tangible net worth requirement and a required asset coverage ratio.

For the three months ended March 31, 2023, the weighted average outstanding principal balance was $333.2 million and the weighted average effective interest rate was 7.80%. For the three months ended March 31, 2022, the weighted average outstanding principal balance was $89.4 million and the weighted average effective interest rate was 3.91%.

December 2026 Notes

On December 10, 2021, the Company completed a private debt offering of $70.0 million in aggregate principal amount of 4.25% interest-bearing unsecured Series 2021A Senior Notes due 2026 (the “December 2026 Notes”) to institutional accredited investors (as defined in Regulation D under the Securities Act of 1933, as amended (the "Securities Act"). The December 2026 Notes were issued in two closings, the initial issuance of $20.0 million December 2026 Notes closed on December 10, 2021 and the second and final issuance of $50.0 million closed on February 10, 2022.

The December 2026 Notes bear an interest rate of 4.25% per year and are due on December 10, 2026, unless redeemed, purchased or prepaid prior to such date by the Company or its affiliates in accordance with their terms. Interest on the December 2026 Notes will be due semiannually in arrears on June 10 and December 10 of each year, commencing on June 10, 2022. The interest rate is subject to a 1.00% increase in the event that, subject to certain exceptions, the December 2026 Notes cease to have an investment grade rating or receive an investment grade rating below the Investment Grade (as defined in the note purchase agreement). The December 2026 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

Aggregate offering costs in connection with the December 2026 Notes issuance, including the underwriter’s discount and commissions, were $1.0 million, which were capitalized and deferred. As of March 31, 2023 and December 31, 2022, unamortized deferred debt costs related to the December 2026 Notes were $0.8 million and $0.8 million, respectively.

July 2027 Notes

On July 28, 2022, the Company issued and sold $80.5 million in aggregate principal amount of 7.50% interest-bearing unsecured Notes due 2027 (the “July 2027 Notes”) under its shelf Registration Statement on Form N-2. The July 2027 Notes were issued pursuant to the Base Indenture dated July 28, 2022 (the “Base Indenture”) and First Supplemental Indenture, dated July 28, 2022 (together with the Base Indenture, the “Indenture”), between the Company and the Trustee, U.S. Bank Trust Company, National Association.

The July 2027 Notes bear an interest rate of 7.50% per year and are due on July 28, 2027. Interest on the 2027 Notes will be due quarterly in arrears on March 1, June 1, September 1 and December 1 of each year, commencing September 1, 2022. The July 2027 Notes may be redeemed in whole or in part at any time or from time to time at the Company’s option on or after July 28, 2024, at a redemption price of $25 per July 2027 Note plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to the date fixed for redemption. The July 2027 Notes are general unsecured obligations of the Company that rank pari passu with the Company's existing and future unsecured, unsubordinated indebtedness.

Table of Contents

Aggregate offering costs in connection with the July 2027 Notes issuance, including the underwriter’s discount and commissions, were $2.6 million, which were capitalized and deferred. As of March 31, 2023 and December 31, 2022, unamortized deferred debt costs related to the July 2027 Notes were $2.3 million and $2.4 million, respectively.

August 2027 Notes

On August 31, 2022, the Company issued and sold a private debt offering of $20.0 million in aggregate principal amount of 7.00% interest-bearing unsecured Series 2022A Senior Notes due 2027 (the “August 2027 Notes”) to HCM Master Fund Limited.

The August 2027 Notes bear an interest rate of 7.00% per year and are due on August 31, 2027, unless redeemed, purchased or prepaid prior to such date by the Company or its affiliates in accordance with their terms. Interest on the August 2027 Notes will be due semiannually in arrears on February 15 and August 15 of each year, commencing on February 15, 2023. The August 2027 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

Aggregate offering costs in connection with the August 2027 Notes issuance, including the underwriter’s discount and commissions, were $0.7 million, which were capitalized and deferred. As of March 31, 2023 and December 31, 2022, unamortized deferred debt costs related to the August 2027 Notes were $0.6 million and $0.7 million, respectively.

December 2027 Notes

On December 7, 2022, the Company issued and sold $51.75 million in aggregate principal amount of 8.00% interest-bearing unsecured Notes due December 2027 (the "December 2027 Notes") under its shelf Registration Statement on Form N-2. The December 2027 Notes were issued pursuant to the Base Indenture dated July 28, 2022 (the "Base Indenture") and Second Supplemental Indenture, dated December 7, 2022 (together with the Base Indenture, the "Indenture"), between the Company and the Trustee, U.S. Bank Trust Company, National Association.

The December 2027 Notes bear an interest rate of 8.0% per year and are due on December 28, 2027. Interest on the 2027 Notes will be due quarterly in arrears on March 1, June 1, September 1, and December 1 of each year, commencing March 1, 2023. The December 2027 Notes may be redeemed in whole or in part at any time or from time to time at the Company's option on or after December 31, 2024, at a redemption price of $25 per December 2027 Note plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to the date fixed for redemption. The December 2027 Notes are general unsecured obligations of the Company that rank pari passu with the Company's existing and future unsecured, unsubordinated indebtedness.

Aggregate offering costs in connection with the December 2027 Notes issuance, including the underwriter's discount and commissions, were $1.8 million, which were capitalized and deferred. As of March 31, 2023 and December 31, 2022, unamortized deferred debt costs related to the December 2027 Notes were $1.7 million and $1.8 million, respectively.

Table of Contents

Note 12 – Financial Highlights


	Three Months Ended March 31,
	(In thousands, except share and per share data)
	2023			2022
	(Unaudited)			(Unaudited)
Per Share Data(1):
Net asset value at beginning of period	$	14.22		$	14.65
Net investment income(3)		0.45			0.30
Realized gain (loss)		(0.03)			(0.01)
Change in unrealized appreciation (depreciation)		(0.12)			(0.22)
Dividends		(0.45)			(0.27)
Offering costs		—			—
Accretion (dilution)(4)		—			—
Net asset value at end of period	$	14.07		$	14.45

Total return based on net asset value(2)		(1.05)	%		(1.37)	%
Weighted average shares outstanding for the period, basic		40,509,269			41,375,187
Ratio/Supplemental Data:
Net assets at end of period	$	569,807		$	597,466
Average net assets(5)	$	583,731		$	611,815
Ratio of net operating expenses to average net assets(6)(7)		12.25	%		3.84	%
Ratio of net increase (decrease) in net assets resulting from operations to average net assets(7)		10.71	%		2.56	%
Portfolio turnover rate(8)		1.15	%		1.46	%

(1)

Financial highlights are based on weighted-average shares outstanding.

(2)

Total return based on net asset value is based upon the change in net asset value per share between the opening and ending net asset values per share in the period. The total returns are not annualized.

(3)

Return from investment operations was 3.16% and 2.05% for the three months ended March 31, 2023 and 2022, respectively. Return from investment operations represents returns on net investment income from operations.

(4)

Return from accretion was 0.00% and 0.00% for the three months ended March 31, 2023 and 2022, respectively.

(5)

The annualized ratio of net investment income to average net assets was 15.07% and 8.93% for the three months ended March 31, 2023 and 2022, respectively.

(6)

The annualized ratio of net operating expenses excluding incentive fees, to average net assets was 11.46% and 3.62% for the three months ended March 31, 2023 and 2022, respectively.

(7)

Incentive fees are not annualized.

(8)

The portfolio turnover rate for the three months ended March 31, 2023 and 2022 equals the lesser of investment portfolio purchases or sales during the period, divided by the average investment portfolio value during the period. As such, portfolio turnover rate is not annualized.

Table of Contents

Note 13 - Subsequent Events

The Company evaluated events subsequent to March 31, 2023 through May 9, 2023.

On April 11, 2023, Mustang Bio, Inc. prepaid its outstanding principal balance of $30.0 million on the senior secured loan.

On April 13, 2023, the Company issued the First Supplement to the Series 2021A Senior Notes governing the issuance of $25.00 million in aggregate principal amount of its 8.54% Series 2023A Notes due April 13, 2026 ("The April 2026 Notes"). The April 2026 Notes bear an interest rate of 8.54% per year and are due on April 13, 2026, unless redeemed, purchased, or prepaid prior to such date by the Company or its affiliates in accordance with their terms. Interest on the April 2026 Notes will be due semiannually, beginning October 13, 2023.

On April 25, 2023, the Marley Spoon AG Loan and Security Agreement was amended to: (a) extend the amortization date to January 15, 2025, (b) extend the maturity date to June 15, 2026, (c) PIK all interest through September 15, 2023, (d) add a deferral fee of €592,093 due at the maturity date; and (e) allow for a reduction in the applicable margin based on principal repayment milestones.

On April 28, 2023, the Company funded an investment of $2.0 million to Intellisite Holdings, Inc. (dba Epic IO Technologies, Inc).

On May 2, 2023, the Board of Directors declared an ordinary distribution of $0.40 per share and a supplemental distribution of $0.05 per share for stockholders of record on May 15, 2023 payable on or before May 31, 2023.

On May 5, 2023, the Company funded an investment of $13.9 million to Kin Insurance, Inc.

On May 8, 2023, the investment to TRACON Pharmaceuticals, Inc. was terminated and all obligations under the contract were fully satisfied.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

This quarterly report on Form 10‑Q contains forward-looking statements that involve substantial risks and uncertainties. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective portfolio investments, our industry, our beliefs and opinions, and our assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “will,” “may,” “continue,” “believes,” “seeks,” “estimates,” “would,” “could,” “should,” “targets,” “projects,” “outlook,” “potential,” “predicts” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including without limitation:

•

changes in political, economic or industry conditions, the interest rate environment or conditions affecting the financial and capital markets;

•

an economic downturn or recession, as well as the impairment or failure of financial institutions on both global and domestic scale, could impair our portfolio companies’ ability to continue to operate, which could lead to the loss of some or all of our investments in such portfolio companies;

•

such an economic downturn could disproportionately impact the companies that we intend to target for investment, potentially causing us to experience a decrease in investment opportunities and diminished demand for capital from these companies;

•

a contraction of available credit and/or an inability to access the equity markets that could impair our lending and investment activities;

•

interest rate volatility that could adversely affect our results, particularly to the extent that we use leverage as part of our investment strategy;

•

the impact of interest and inflation rates on our business prospects and the prospects of our portfolio companies;

•

our business prospects and the prospects of our portfolio companies;

•

our contractual arrangements and relationships with third parties;

•

the ability of our portfolio companies to achieve their objectives;

•

competition with other entities and our affiliates for investment opportunities;

•

the speculative and illiquid nature of our investments;

•

the use of borrowed money to finance a portion of our investments;

•

the adequacy of our financing sources and working capital;

•

the loss of key personnel;

•

the timing of cash flows, if any, from the operations of our portfolio companies and the impact of the COVID‑19 pandemic thereon;

•

the ability of our external investment adviser, Runway Growth Capital LLC (“RGC”), to locate suitable investments for us and to monitor and administer our investments;

•

the ability of RGC to attract and retain highly talented professionals;

•

our ability to qualify and maintain our qualification as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”), and as a business development company (“BDC”);

Table of Contents

•

the occurrence of a disaster, such as a cyber-attack against us or against a third party that has access to our data or networks, a natural catastrophe, an industrial accident, failure of our disaster-recovery systems, or consequential employee error;

•

the effect of legal, tax, and regulatory changes; and

•

the other risks, uncertainties and other factors we identify under “Risk Factors” in Part I, Item 1A of our annual report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (the "SEC") on March 2, 2023.

Although we believe the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate, and as a result, the forward-looking statements based on those assumptions also could be inaccurate. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this quarterly report on Form 10-Q should not be regarded as a representation by us that our plans and objectives will be achieved. These risks and uncertainties include those described or identified in “Risk Factors” in in Part I, Item 1A of our annual report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023.

We have based the forward-looking statements included in this Form 10‑Q on information available to us on the date of this Form 10‑Q, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation to revise or update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we have filed or in the future may file with the SEC, including our annual reports on Form 10‑K, quarterly reports on Form 10‑Q and current reports on Form 8‑K.

The following analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto contained elsewhere in this quarterly report on Form 10‑Q.

Overview

Runway Growth Finance Corp. ("we," "us," "our," or the "Company"), a Maryland corporation formed on August 31, 2015, is structured as an externally managed, non-diversified closed-end management investment company. On August 18, 2021, we changed our name to "Runway Growth Finance Corp." from "Runway Growth Credit Fund Inc." We are a specialty finance company focused on providing senior secured loans to high growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products and other high-growth industries. Our goal is to create significant value for our stockholders and the entrepreneurs we support by providing high growth-potential companies with hybrid debt and equity financing that is more flexible than traditional credit and less dilutive than equity. Our investment objective is to maximize our total return to our stockholders primarily through current income on our loan portfolio, and secondarily through capital appreciation on our warrants and other equity positions. Our offices are in Chicago, Illinois; Menlo Park, California; San Diego, California; Dallas, Texas; and New York, New York.

We have elected to be regulated as a business development company ("BDC") under the Investment Company Act of 1940, as amended (together with the rules and regulations promulgated thereunder, the "1940 Act"). We have also elected to be treated as regulated investment company ("RIC") under Subchapter M of the Internal Revenue Code of 1986, as amended (the "Code"), currently qualify, and intend to continue to qualify annually for treatment as a RIC. While we intend to qualify to be treated as a RIC annually, no assurance can be provided that we will be able to maintain our tax treatment as a RIC. If we fail to qualify for tax treatment as a RIC for any taxable year, we will be subject to U.S. federal income tax at corporate rates on any net taxable income for such year. As a BDC and a RIC, we are required to comply with various regulatory requirements, such as the requirement to invest at least 70% of our assets in “qualifying assets,” source-of-income limitations, asset diversification requirements, and the requirement to distribute annually at least 90% of our investment company taxable income and net tax-exempt interest.

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). We will remain an emerging growth company until the last day of our fiscal year following the fifth anniversary of our IPO on October 25, 2021, or until the earliest of (i) the last day of the first fiscal year in which we have total annual gross revenue of $1.235 billion or more, (ii) December 31 of the fiscal year in which we become a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (together with the rules and regulations promulgated thereunder, the “Exchange Act”), (which would occur if the market value of our common stock held by non-affiliates exceeds $700.0 million, measured as of the last business day of our most recently completed second fiscal quarter, and we have been publicly reporting for at least 12 months), or (iii) the date on which we have issued more than $1.0 billion in non-convertible debt during the preceding three-year period. For so long as we remain an emerging growth company under the JOBS Act, we will be subject to reduced public company reporting requirements.

Table of Contents

We are externally managed by RGC, an investment adviser that has registered with the SEC under the Investment Advisers Act of 1940, as amended. The Administrator, a wholly-owned subsidiary of RGC, provides all the administrative services necessary for us to operate.

On August 10, 2020, we, RGC, and certain other funds and accounts sponsored or managed by RGC and/or its affiliates were granted the Order that permits us greater flexibility than the 1940 Act permits to negotiate the terms of co-investments if our Board of Directors determines that it would be advantageous for us to co-invest with other accounts sponsored or managed by RGC or its affiliates in a manner consistent with the our investment objective, positions, policies, strategies and restrictions as well as regulatory requirements and other pertinent factors. We believe that the ability to co-invest with similar investment structures and accounts sponsored or managed by RGC or its affiliates will provide additional investment opportunities and the ability to achieve greater diversification. Under the terms of the Order, a majority of our independent directors are required to make certain determinations in connection with a co-investment transaction, including that (1) the terms of the proposed transaction are reasonable and fair to us and our stockholders and do not involve overreaching of us or our stockholders on the part of any person concerned and (2) the transaction is consistent with the interests of our and is consistent with our investment strategies and policies.

On August 30, 2022, we received an amendment to our existing Order to permit us to, subject to the satisfaction of certain conditions, co-invest in our existing portfolio companies with certain affiliates that are private funds even if such other funds had not previously invested in such existing portfolio company. Without this order, such affiliated funds that are private funds would not be able to participate in such co-investments with us unless the affiliated funds had previously acquired securities of the portfolio company in a co-investment transaction with us.

Portfolio Composition and Investment Activity

Portfolio Composition

At March 31, 2023, we had investments in 49 portfolio companies, representing 26 companies in which we held loan and warrant investments, two companies in which we held loan investments and shares of common, preferred stock, or a combination with warrants, six companies in which we held a loan investment only, ten companies in which we held warrant investments only, and five companies in which we held shares of common or preferred stock only, or a combination with warrants. The following table shows the fair value of our investments, by asset class, as of March 31, 2023 (in thousands):


Investments	Cost		Fair Value		% of Total Portfolio
Portfolio Investments
Common Stocks	$	8,715	$	1,965		0.17	%
Preferred Stocks		37,382		34,884		3.01
Senior Secured Term Loans		1,076,440		1,060,495		91.40
Second Lien Term Loans		13,853		13,707		1.18
Warrants		18,325		14,291		1.23
Total Portfolio Investments		1,154,715		1,125,342		96.99

U.S. Treasury Bill		34,978		34,974		3.01
Total Investments	$	1,189,693	$	1,160,316		100.00	%

At December 31, 2022, we had investments in 49 portfolio companies, representing 28 companies in which we held loan and warrant investments, one companies in which we held loan investments and shares of common, preferred stock, or a combination with warrants, six companies in which we held a loan investment only, nine companies in which we held warrant investments only, and five companies in which we held shares of common or preferred stock only, or a combination with warrants. The following table shows the fair value of our investments, by asset class, as of December 31, 2022 (in thousands):


Investments	Cost		Fair Value		% of Total Portfolio
Portfolio Investments
Common Stocks	$	8,715	$	3,097		0.27	%
Preferred Stocks		12,382		12,682		1.13
Senior Secured Term Loans		1,096,724		1,080,121		95.90
Second Lien Term Loans		13,654		13,654		1.21
Warrants		19,127		16,755		1.49
Total Portfolio Investments		1,150,602		1,126,309		100.00

U.S. Treasury Bill		—		—		—
Total Investments	$	1,150,602	$	1,126,309		100.00	%

Table of Contents

For the three months ended March 31, 2023, our debt investment portfolio had a dollar-weighted annualized yield of 15.24%. For the three months ended March 31, 2022, our debt investment portfolio had a dollar-weighted annualized yield of 12.15%. We calculate the yield on dollar-weighted debt investments for any period measured as (1) total related investment income during the period divided by (2) the daily average of the fair value of debt investments outstanding during the period. As of March 31, 2023, our debt investments had a dollar-weighted average outstanding term of 56 months at origination and a dollar-weighted average remaining term of 42 months, or approximately 3.5 years. As of March 31, 2023, substantially all of our debt investments had an original committed principal amount of between $6.0 million and $85.0 million, repayment terms of between 37 months and 82 months and pay cash interest at annual interest rates of between 5.94% and 16.29%.

The following table shows our dollar-weighted annualized yield by investment type for the three months ended March 31, 2023 and 2022:


	Fair Value(1)						Cost(2)
	Three Months Ended March 31,						Three Months Ended March 31,
	2023			2022			2023			2022
Investment type:
Debt investments		15.24	%		12.15	%		14.99	%		12.03	%
Equity interest		3.18	%		3.36	%		2.71	%		3.91	%
All investments		14.78	%		11.54	%		14.45	%		11.55	%

(1)

We calculate the dollar-weighted annualized yield on average investment type for any period as (a) total related investment income during the period divided by (b) the daily average of the fair value of the investment type outstanding during the period. The dollar-weighted annualized yield represents the portfolio yield and will be higher than what investors will realize because it does not reflect our expenses or any sales load paid by investors.

(2)

We calculate the dollar-weighted annualized yield on average investment type for any period as (a) total related investment income during the period divided by (b) the daily average of the investment type outstanding during the period, at amortized cost. The dollar-weighted annualized yield represents the portfolio yield and will be higher than what investors will realize because it does not reflect our expenses or any sales load paid by investors.

Investment Activity

The value of our investment portfolio will change over time due to changes in the fair value of our underlying investments, as well as changes in the composition of our portfolio resulting from purchases of new and follow-on investments as well as repayments and sales of existing investments. During the three months ended March 31, 2023, the Company did not fund any new portfolio companies and funded $12.9 million in five existing portfolio companies, net of upfront loan origination fees. The Company also received $10.2 million in loan repayments from two portfolio companies. There were no proceeds from the termination of warrants, sale of preferred stock, and sale of common stock. During the three months ended March 31, 2022, the Company funded $42.1 million in two new portfolio companies and $40.7 million in four existing portfolio companies, net of upfront loan origination fees. The Company also received $7.6 million in loan repayments from one portfolio company and $0.3 million in proceeds from the termination of warrants.

Portfolio Reconciliation

The following is a reconciliation of our investment portfolio, including U.S. Treasury Bills, for the three months ended March 31, 2023 and 2022 (in thousands):


		Three Months Ended March 31,
	2023				2022
Beginning Investment Portfolio	$		1,126,309		$	729,516
Purchases of Investments			12,871			85,520
Purchases of U.S. Treasury Bills			34,974			-
PIK interest			3,755			1,337
Sales or Repayments of Investments			(10,192	)		(9,878	)
Scheduled Principal Payments of Investments			(4,007	)		(424	)
Sales and Maturities of U.S. Treasury Bills(1)			-			(45,000	)
Realized Gain (Loss) on Investments			(1,178	)		(371	)
Net Change in Unrealized Appreciation (Depreciation) on Investments			(5,084	)		(9,235	)
Amortization of Fixed Income Premiums or Accretion of Discounts			2,868			2,825
Ending Investment Portfolio	$		1,160,316		$	754,290

Table of Contents

Asset Quality

In addition to various risk management and monitoring tools, RGC uses an investment rating system to characterize and monitor the quality of our debt investment portfolio. Equity securities and Treasury Bills are not graded. This debt investment rating system uses a five-level numeric scale. The following is a description of the conditions associated with each investment rating:


Investment Rating		Rating Definition

1		Performing above plan and/or strong enterprise profile, value, financial performance/coverage. Maintaining full covenant and payment compliance as agreed.
2		Performing at or reasonably close to plan. Acceptable business prospects, enterprise value, financial coverage. Maintaining key covenant and payment compliance as agreed. All new loans are initially graded Category 2.
3		Performing below plan of record. Potential elements of concern over performance, trends and business outlook. Loan-to-value remains adequate. Potential key covenant non-compliance. Full payment compliance.
4		Performing materially below plan. Non-compliant with material financial covenants. Payment default/deferral could result without corrective action. Requires close monitoring. Business prospects, enterprise value and collateral coverage declining. These investments may be in workout, and there is a possibility of loss of return but no loss of principal is expected.
5		Going concern nature in question. Substantial decline in enterprise value and all coverages. Covenant and payment default imminent if not currently present. Investments are nearly always in workout. May experience partial and/or full loss.

The following table shows the investment ratings of our debt investments at fair value as of March 31, 2023 and December 31, 2022 (dollars in thousands):


	March 31, 2023 (Unaudited)							December 31, 2022
Investment Rating	Fair Value		% of Total Portfolio			Number of Portfolio Companies		Fair Value		% of Total Portfolio			Number of Portfolio Companies
1	$	—		—	%		—	$	—		—	%		0
2		963,556		83.0			28		1,006,247		89.3			30
3		99,033		8.5			5		78,238		7.0			4
4		—		—			—		—		—			0
5		11,613		1.0			1		9,290		0.8			1
	$	1,074,202		92.6	%		34	$	1,093,775		97.1	%		35

During 2023 and 2022, the global COVID-19 pandemic has had limited impact on the investment ratings of our debt investments, taken as a whole. However, the ongoing impact of the global COVID-19 pandemic, along with the increasing levels of inflation impacting the U.S. economy, U.S. Federal Reserve Bank monetary policy actions, and global political events and their impact on the U.S. capital markets and economy is uncertain and we can make no assurances that the pandemic or other current events will not have a negative impact on our investment portfolio in the future.

Loans and Debt Securities on Non-Accrual Status

Generally, when interest and/or principal payments on a loan become past due, or if we otherwise do not expect the borrower to be able to service its debt and other obligations, we will place the loan on non-accrual status and will cease recognizing interest income on that loan for financial reporting purposes until all principal and interest have been brought current through payment or due to a restructuring such that the interest income is deemed to be collectible. As of March 31, 2023, and December 31, 2022, we have not written off any accrued and uncollected PIK interest. As of March 31, 2023, we had one loan to Pivot3, Inc. on non-accrual status. The loan, with a cost basis of $19.2 million and a fair value of $11.6 million, represents 1.00% of the total investment portfolio. From being placed on non-accrual status through March 31, 2023, cumulative interest of $4.3 million would be receivable and $0.3 million OID would be accreted into the cost basis, for a total of $4.6 million not recorded in interest income from control investments on the Statement of Operations. As of December 31, 2022, we had one loan to Pivot3, Inc. on non-accrual status. The loan, with a cost basis of $19.2 million and a fair market value of $9.3 million, represents 0.8% of the total investment portfolio. From being placed on non-accrual status through December 31, 2022, cumulative interest of $3.6 million would be payable and $0.3 million OID would be accreted into the cost basis, for a total of $3.9 million not recorded in interest income from control investments on the Statement of Operations.

Table of Contents

Results of Operations

An important measure of our financial performance is net increase/(decrease) in net assets resulting from operations, which includes net investment income/(loss), net realized gain/(loss) and net unrealized appreciation/(depreciation). Net investment income/(loss) is the difference between our income from interest, dividends, fees and other investment income and our operating expenses, including interest on borrowed funds. Net realized gain/(loss) on investments is the difference between the proceeds received from dispositions of portfolio investments and their amortized cost. Net unrealized appreciation/(depreciation) on investments is the net change in the fair value of our investment portfolio.

The following table is a comparison of the results of our operations for the three months ended March 31, 2023 and 2022 (dollars in thousands):


	Three Months Ended March 31,
	2023						2022
	Total			Per Share(1)			Total			Per Share(1)
Investment income
Interest and dividend income	$	39,265		$	0.97		$	18,841		$	0.46
Other income		45			—			391			0.01
Total investment income		39,310			0.97			19,232			0.46
Operating expenses
Management fees		3,959			0.10			2,560			0.06
Incentive fees		4,563			0.11			1,344			0.03
Interest and other debt financing expenses		10,920			0.27			1,579			0.04
Professional fees		533			0.01			394			0.01
Overhead allocation expense		345			0.01			237			0.01
Insurance expense		268			0.01			269			0.01
Administration fee		162			—			169			—
Directors' fees		84			—			89			—
Tax expense		50			—			—			—
Other expenses		180			—			132			—
Total operating expenses		21,064			0.52			6,773			0.16
Net investment income		18,246			0.45			12,459			0.30
Realized gain (loss) on investments		(1,178	)		(0.03	)		(371	)		(0.01	)
Net change in unrealized appreciation (depreciation) on investments		(5,084	)		(0.13	)		(9,235	)		(0.22	)
Net increase (decrease) in net assets resulting from operations	$	11,984		$	0.30		$	2,853		$	0.07

(1)

The basic per share figures noted above are based on weighted averages of 40,509,269 and 41,375,187 shares outstanding for the three months ended March 31, 2023 and 2022, respectively.

Investment Income

Our investment objective is to maximize total return to our stockholders primarily through current income on our loan portfolio, and secondarily through capital appreciation on our warrants and other equity positions. We intend to achieve our investment objective by investing in high growth-potential, private companies. We typically invest in senior secured and second lien secured loans that generally fall into two strategies: Sponsored Growth Lending and Non-Sponsored Growth Lending. Our Sponsored Growth Lending strategy also typically includes the receipt of warrants and/or other equity from venture-backed companies. We expect our investments in loans will generally range from between $10.0 million to $100.0 million, and the upper end of this range may increase as we raise additional capital.

We generate revenue in the form of interest on the debt securities that we hold and distributions and capital gains on other interests that we acquire in our portfolio companies. We expect that the debt we invest in will generally have stated terms of 36 to 60 months. Interest on debt securities is generally payable quarterly or semiannually, primarily based on a floating rate index, and subject to certain floors determined by market rates at the time the investment is made. In some cases, some of our investments may provide for deferred interest payments or PIK interest. The principal amount of the debt securities and any accrued but unpaid interest generally will become due at the maturity date. In addition, we may generate revenue in the form of commitment and other fees in connection with transactions. Any original issue discount ("OID") or market discount or premium will be capitalized, and we will accrete or amortize such amounts as interest income. We record prepayment premiums on loans and debt securities as interest income. Dividend income, if any, will be recognized on an accrual basis to the extent that we expect to collect such amounts.

Table of Contents

Non-recurring income included in investment income are unamortized original issue discounts recorded as interest income. Other non-recurring income consisting of early prepayment fees, amendment fees, legal fees, and reimbursable income are recorded as fee income when earned. Any other fee income for services rendered, if any, are recorded as other income when earned.

Investment income for the three months ended March 31, 2023 and 2022 was $39.3 million and $19.2 million, respectively, and includes non-recurring income of $0.6 million and $0.8 million, respectively. The increase in investment income for the three months ended March 31, 2023 compared to the three months ended March 31, 2022 was primarily due to interest income and driven by our deployment of capital, increased invested balance, and increased market interest rates.

Operating Expenses

Our primary operating expenses include the payment of fees to RGC under the Advisory Agreement, our allocable portion of overhead expenses under the Administration Agreement, professional fees, and other operating costs described below. We bear all other out-of-pocket costs and expenses of our operations and transactions, including those relating to:

•

our pro-rata portion of fees and expenses related an initial public offering in connection with a Spin-Off transaction (as defined below);

•

fees and expenses related to public and private offerings, sales and repurchases of our securities;

•

calculating our net asset value (including the cost and expenses of any independent valuation firm);

•

fees and expenses payable to third parties, including agents, consultants or other advisers, in connection with monitoring financial and legal affairs for us and in providing administrative services, monitoring our investments and performing due diligence on our prospective portfolio companies or otherwise relating to, or associated with, evaluating and making investments;

•

interest payable on debt incurred to finance our investments;

•

sales and purchases of our common stock and other securities;

•

investment advisory and management fees;

•

administration fees payable under the Administration Agreement;

•

transfer agent and custodial fees;

•

federal and state registration fees;

•

all costs of registration and listing our securities on any securities exchange;

•

U.S. federal, state and local taxes;

•

independent directors’ fees and expenses;

•

costs of preparing and filing reports or other documents required by the SEC, the Financial Industry Regulatory Authority or other regulators;

•

costs of any reports, proxy statements or other notices to stockholders, including printing costs;

•

our allocable portion of any fidelity bond, directors’ and officers’ errors and omissions liability insurance, and any other insurance premiums;

•

direct costs and expenses of administration, including printing, mailing, long distance telephone, copying, secretarial and other staff, independent auditors and outside legal costs; and

•

all other expenses incurred by us, our Administrator or RGC in connection with administering our business, including payments under the Administration Agreement based on our allocable portion of our Administrator’s overhead in performing its obligations under the Administration Agreement, including rent and the allocable portion of the cost of our Chief Compliance Officer and Chief Financial Officer and their respective staffs.

Operating expenses for the three months ended March 31, 2023 and 2022 were $21.1 million and $6.8 million, respectively. Operating expenses increased for the three months ended March 31, 2023 from the three months ended March 31, 2022 primarily due to an increase in incentive fees, management fees, debt financing fees, and interest expense. Operating expenses for the three months ended March 31, 2023 and 2022 were $0.52 and $0.16 per share, respectively.

Table of Contents

Incentive Fees

Incentive fees for the three months ended March 31, 2023 and 2022 were $4.6 million and $1.3 million, respectively. Incentive fees increased for the three months ended March 31, 2023 from the three months ended March 31, 2022 primarily due to an increase in net investment income. For the three months ended March 31, 2023, $3.5 million of the incentive fees were earned, payable in cash, and $1.1 million were deferred and accrued. For the three months ended March 31, 2022, $1.1 million of the incentive fees were earned, payable in cash, and $0.3 million were deferred and accrued. Incentive fees related to PIK or deferred interest are accrued and payment is deferred until such interest is collected in cash. Incentive fees for the three months ended March 31, 2023 and 2022 were $0.11 and $0.03 per share, respectively.

Net Investment Income

Net investment income for the three months ended March 31, 2023 and 2022 was $18.2 million and $12.5 million, respectively. Net investment income increased for the three months ended March 31, 2023 from the three months ended March 31, 2022 was primarily due to rising interest rates. Net investment income for the three months ended March 31, 2023 and 2022 was $0.45 and $0.30 per share, respectively.

Net Realized Gain (Loss) on Investments

The net realized loss on investments of $1.2 million for the three months ended March 31, 2023 was due to a loss of our investments in the warrants of CareCloud, Inc. and Gynesonics, Inc. The net realized loss on investments of $0.4 million for the three months ended March 31, 2022 was primarily due to the loss on a portion of our investment in the preferred stock and warrants of CareCloud, Inc., partially offset by the gain on our investment in the warrants of CrossRoads Extremity Systems, LLC.

Net Change in Unrealized Appreciation (Depreciation) on Investments

Net change in unrealized depreciation on investments of $5.1 million for the three months ended March 31, 2023 was primarily due to decreases in the fair value of our senior secured loan to Gynesonics, Inc. and preferred stock in Gynesonics, Inc., partially offset by an increase in the fair value of our senior secured loan to Pivot3, Inc. The net change in unrealized depreciation on investments of $9.2 million for the three months ended March 31, 2022 was primarily due to decreases in the fair value of our investment in the common stock of Brilliant Earth Group, Inc. and preferred stock in CareCloud, Inc.

Net Increase (Decrease) in Net Assets Resulting from Operations

We had a net increase in net assets resulting from operations of $12.0 million for the three months ended March 31, 2023, as compared to a net increase in net assets resulting from operations of $2.9 million for the three months ended March 31, 2022. The net increase in net assets resulting from operations for the three months ended March 31, 2023 from the three months ended March 31, 2022 was primarily due to an increase in net investment income arising from increased interest rates offset by an increase in debt financing fees and interest expense for the three months ended March 31, 2023.

Financial Condition, Liquidity and Capital Resources

We generate cash primarily from the net proceeds of the offering of our securities and cash flows from our operations, including investment sales and repayments as well as income earned on investments and cash equivalents. We may also fund a portion of our investments through borrowings under the Credit Facility. We expect that we may also generate cash from any financing arrangements we may enter into in the future and any future offerings of our equity or debt securities. We may fund a portion of our investments through borrowings from banks and issuances of senior securities, which may be secured or unsecured, through registered offerings or private placements. Our primary use of funds is to make investments in eligible portfolio companies, pay our operating expenses and make distributions to holders of our common stock.

As of March 31, 2023 and December 31, 2022, our asset coverage ratio was 196.0% and 203.0%, respectively.

During the three months ended March 31, 2023, cash and cash equivalents decreased to $3.3 million from $5.8 million as of December 31, 2022. This decrease was primarily the result of repayment of borrowings under the Credit Facility.

Table of Contents

Equity Activity

We have the authority to issue 100,000,000 shares of common stock, $0.01 par value per share.

The shares of common stock issued, the price per share and the proceeds raised, from inception through March 31, 2023 are detailed in the following table (in thousands, except for share and per share data):


Issuance Date	Shares Issued			Price per Share			Gross Proceeds
October 8, 2015		1,667	$		15.00	$		25
December 22, 2016		333,333			15.00			5,000
April 19, 2017		1,000,000			15.00			15,000
June 26, 2017		1,666,667			15.00			25,000
September 12, 2017		2,666,667			15.00			40,000
December 22, 2017		3,000,000			15.00			45,000
May 31, 2018(1)		70,563			14.82			1,046
August 31, 2018(1)		117,582			14.92			1,754
September 27, 2018		1,997,337			15.02			30,000
November 15, 2018(1)		202,779			15.07			3,055
January 14, 2019		4,344,964			15.19			66,000
March 26, 2019(1)		326,431			15.14			4,942
May 21, 2019(1)		374,783			15.13			5,670
May 24, 2019		3,232,189			15.16			49,000
July 16, 2019(1)		464,986			15.13			7,035
August 26, 2019(1)		480,121			14.76			7,088
October 15, 2019		1,666,667			15.00			25,000
November 12, 2019(1)		43,979			14.76			649
December 20, 2019		3,333,333			15.00			50,000
December 23, 2019(1)		487,166			14.52			7,074
March 20, 2020(1)		575,132			14.58			8,385
March 31, 2020		21,021			15.00			315
May 20, 2020(1)		529,020			14.25			7,539
August 6, 2020(1)		550,639			14.41			7,935
October 15, 2020		3,333,333			15.00			50,000
November 12, 2020(1)		593,692			14.46			8,585
March 19, 2021(1)		618,815			14.84			9,183
March 24, 2021		20,461			15.00			307
May 13, 2021(1)		637,127			14.77			9,410
August 12, 2021(1)		575,032			14.61			8,401
September 29, 2021		1,265,128			15.00			18,977
October 25, 2021		6,850,000			14.60			100,010
Total		41,380,614				$		617,386

(1)

Shares were issued as part of the Dividend Reinvestment Plan.

Stock Repurchase Plans

On February 24, 2022, the Board of Directors approved the Repurchase Program under which the Company may repurchase up to $25.0 million of its outstanding common stock. Under the Repurchase Program, purchases may be made at management’s discretion from time to time in open-market transactions, in accordance with all applicable securities laws and regulations. The Repurchase Program was not renewed by the Board of Directors, and expired on February 24, 2023.

The following table provides information relating to repurchases of our common stock since inception of the Repurchase Program through March 31, 2023:


	Total Number of Shares Repurchased			Average Price Paid Per Share		Approximate Dollar Value of Shares That Have Been Purchased Under the Plan (in thousands)		Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plan (in thousands)
Quarter ended March 31, 2022		31,782	$		12.88	$	409	$	24,591
Quarter ended June 30, 2022		381,710			12.76		4,870		19,721
Quarter ended September 30, 2022		331,264			12.14		4,023		15,698
Quarter ended December 31, 2022		126,589			11.96		1,514		14,184
Quarter ended March 31, 2023		—			—		—		—
Total		871,345				$	10,816

Table of Contents

Contractual Obligations

As of March 31, 2023, the Company had $302.7 million in unfunded loan commitments to provide debt financing to its portfolio companies. The availability of such unfunded loan commitments is subject to the specific terms and conditions of each contract, which may include, among other things, portfolio company performance requirements and time-based cancellation provisions. As a result, only a portion of unfunded commitments is currently eligible to be drawn. We believe that our available cash balances and availability under the Credit Facility, provides sufficient funds to cover our unfunded commitments as of March 31, 2023. Refer to “Note 11 – Borrowings” to our financial statements in Part I, Item 1 of this Form 10‑Q for more information on the Company's borrowings.

The following table provides a summary of unfunded loan commitments by portfolio company as of March 31, 2023 (in thousands):


Portfolio Company	Investment Type	March 31, 2023
3PL Central LLC (dba Extensiv)	Senior Secured Term Loan	$	12,000
Brivo, Inc.	Senior Secured Term Loan		12,000
CloudPay, Inc.	Senior Secured Term Loan		15,000
Dtex Systems, Inc.	Senior Secured Term Loan		15,000
EBR Systems, Inc.	Senior Secured Term Loan		30,000
Intellisite Holdings, Inc. (dba Epic IO Technologies, Inc.)	Senior Secured Term Loan		2,000
Interactions Corporation	Senior Secured Term Loan		10,000
Kin Insurance, Inc.	Senior Secured Term Loan		25,000
Madison Reed, Inc.	Senior Secured Term Loan		2,400
Moximed, Inc.	Senior Secured Term Loan		15,000
Nalu Medical, Inc.	Senior Secured Term Loan		25,000
Revelle Aesthetics, Inc.	Senior Secured Term Loan		12,500
Route 92 Medical, Inc.	Senior Secured Term Loan		41,564
SetPoint Medical Corporation	Senior Secured Term Loan		40,000
Skillshare, Inc.	Senior Secured Term Loan		15,000
Snagajob.com, Inc.	Senior Secured Term Loan		6,785
Synack, Inc.	Senior Secured Term Loan		23,480
Total unused commitments to extend financing		$	302,729


	Payments Due by Period
	Total		Less than 1 Year			1-3 years			3-5 years		More than 5 Years
Credit Facility	$	372,000	$	—	$		—	$		372,000	$	—
2026 Notes		70,000		—			—			70,000		—
2027 Notes		152,250		—			—			152,250		—
Total	$	594,250	$	—	$		—	$		594,250	$	—

Off-Balance Sheet Arrangements

We currently have no off-balance sheet arrangements, including any risk management of commodity pricing or other hedging practices.

Distributions

To the extent that we have funds available, we intend to make quarterly distributions to our stockholders. Our stockholder distributions, if any, will be determined by our Board of Directors. Any distribution to our stockholders will be declared out of assets legally available for distribution. We anticipate that distributions will be paid from income primarily generated by interest and dividend income earned on investments made by us.

Prior to our IPO, the number of shares to be issued to a stockholder under the Dividend Reinvestment Plan was determined by dividing the total dollar amount of the distribution payable to such stockholder by the net asset value per share of our common stock, as of the valuation date fixed by the Board of Directors for such dividend.

In connection with our IPO, we entered into our amended and restated Dividend Reinvestment Plan, pursuant to which, if newly issued shares are used to implement the Dividend Reinvestment Plan, the number of shares to be issued to a stockholder will be determined by dividing the total dollar amount of the cash dividend or distribution payable to a stockholder by the market price per share of our common stock at the close of regular trading on the Nasdaq Global Select Market LLC on the payment date of a distribution, or if no sale is reported for such day, the average of the reported bid and ask prices. However, if the market price per share on the payment date of a cash dividend or distribution exceeds the most recently computed net asset value per share, we will issue shares at the greater of (i) the most recently computed net asset value per share and (ii) 95% of the current market price per share (or such lesser discount to the current market price per share that still exceeded the most recently computed net asset value per share).

Table of Contents

If shares are purchased in the open market to implement the Dividend Reinvestment Plan, the number of shares to be issued to a shareholder shall be determined by dividing the dollar amount of the cash dividend payable to such shareholder by the weighted average price per share for all shares purchased by the plan administrator in the open market in connection with the dividend.

The number of shares to be issued to a participant in the Dividend Reinvestment Plan are rounded downward to the nearest whole number to avoid the issuance of fractional shares, and any fractional share otherwise issuable to a participant but for this provision is instead be paid to such participant in cash contemporaneously with the issuance of such shares in connection with such cash dividend.

During the three months ended March 31, 2023, we declared and paid dividends in the amount of $18.2 million, of which $17.5 million was distributed in cash and the remainder distributed in shares to stockholders pursuant to the Company’s Dividend Reinvestment Plan. During the year ended December 31, 2022, we declared and paid dividends in the amount of $51.6 million, of which $40.7 million was distributed in cash and the remainder distributed in shares to stockholders pursuant to our Dividend Reinvestment Plan.

The timing and amount of our distributions, if any, will be determined by our Board of Directors and will be declared out of assets legally available for distribution. The following table shows the dividends per share declared since our formation through March 31, 2023.


Declaration Date	Record Date	Payment Date	Amount per Share
May 3, 2018	May 15, 2018	May 31, 2018	$	0.15
July 26, 2018	August 15, 2018	August 31, 2018	$	0.25
November 1, 2018	October 31, 2018	November 15, 2018	$	0.35
March 22, 2019	March 22, 2019	March 26, 2019	$	0.40
May 2, 2019	May 7, 2019	May 21, 2019	$	0.45
May 2, 2019	May 31, 2019	July 16, 2019	$	0.46
July 30, 2019	August 5, 2019	August 26, 2019	$	0.45
September 27, 2019	September 30, 2019	November 12, 2019	$	0.04
December 9, 2019	December 10, 2019	December 23, 2019	$	0.40
March 5, 2020	March 6, 2020	March 20, 2020	$	0.40
May 7, 2020	May 8, 2020	May 21, 2020	$	0.35
August 5, 2020	August 6, 2020	August 20, 2020	$	0.36
October 1, 2020	October 1, 2020	November 12, 2020	$	0.38
March 4, 2021	March 5, 2021	March 19, 2021	$	0.37
April 29, 2021	April 30, 2021	May 13, 2021	$	0.37
July 19, 2021	July 20, 2021	August 12, 2021	$	0.34
October 28, 2021	November 8, 2021	November 22, 2021	$	0.25
February 24, 2022	March 8, 2022	March 22, 2022	$	0.27
April 28, 2022	May 10, 2022	May 24, 2022	$	0.30
July 28, 2022	August 9, 2022	August 23, 2022	$	0.33
October 27, 2022	November 8, 2022	November 22, 2022	$	0.36
February 23, 2023	March 7, 2023	March 21, 2023	$	0.45

Table of Contents

Critical Accounting Policies

Basis of Presentation

The preparation of the financial statements and related disclosures in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reports. Actual results could materially differ from those estimates. We believe that our most critical accounting policies, which are those that are most important to the portrayal of our financial condition and results of operations and require management’s most difficult, subjective and complex judgments, include the valuation of investments and our election to be treated, and intent to qualify annually, as a RIC. Refer to “Note 2 — Summary of Significant Accounting Policies” to our financial statements in Part I, Item 1 of this Form 10‑Q, which describes our critical accounting policies and recently adopted accounting pronouncements not yet required to be adopted by us.

Valuation of Investments

We measure the value of our portfolio investments at fair value in accordance with ASC Topic 820, Fair Value Measurements (“ASC Topic 820”) issued by the FASB. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Audit Committee assists our Board of Directors in valuing investments that are not publicly traded or for which current market values are not readily available. Investments for which market quotations are readily available are valued using market quotations, which are generally obtained from independent pricing services, broker-dealers or market makers. With respect to portfolio investments for which market quotations are not readily available, our Board of Directors, with the assistance of the Audit Committee, RGC and its senior investment team and independent valuation agents, is responsible for determining, in good faith, the fair value of such portfolio investments in accordance with the valuation policy approved by our Board of Directors. If more than one valuation method is used to measure fair value, the results are evaluated and weighted, as appropriate, considering the reasonableness of the range indicated by those results. We consider a range of fair values based upon the valuation techniques utilized and select the value within that range that was most representative of fair value based on current market conditions as well as other factors RGC’s senior investment team considers relevant.

Our Board of Directors makes this fair value determination on a quarterly basis and any other time when a decision regarding the fair value of the portfolio investments is required. A determination of fair value involves subjective judgments and estimates and depends on the facts and circumstances. Due to the inherent uncertainty of determining the fair value of portfolio investments that do not have a readily available market value, the fair value of the investments may differ significantly from the values that would have been used had a readily available market value existed for such investments, and the differences could be material.

•

Level 1—Valuations are based on quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.

•

Table of Contents

With respect to investments for which market quotations are not readily available, our Board of Directors undertakes a multi-step valuation process each quarter, as described below:

•

Our quarterly valuation process begins with each portfolio company investment being initially valued by RGC’s investment professionals that are responsible for the portfolio investment;

•

Preliminary valuation conclusions are then documented and discussed with RGC’s senior investment team;

•

At least once annually, the valuation for each portfolio investment is reviewed by one or more independent valuation firms. Certain investments, however, may not be evaluated by the applicable independent valuation firm if the net asset value and other aspects of such investments in the aggregate do not exceed certain thresholds;

•

The Audit Committee then reviews these preliminary valuations from RGC and the applicable independent valuation firm, if any, and makes a recommendation to our Board of Directors regarding such valuations; and

•

Our Board of Directors reviews the recommended preliminary valuations and determines the fair value of each investment in our portfolio, in good faith, based on the input of RGC, the applicable independent valuation firm and the Audit Committee.

Our investments are primarily loans made to high growth-potential companies focused in technology, life sciences, healthcare information and services, business services, select consumer services and products and other high-growth industries. These investments are considered Level 3 assets under ASC Topic 820 because there is no known or accessible market or market indices for these types of debt instruments and, thus, RGC’s senior investment team must estimate the fair value of these investment securities based on models utilizing unobservable inputs.

Rule 2a-5 under the 1940 Act was adopted by the SEC in December 2020 and establishes a framework for determining fair value in good faith for purposes of the 1940 Act. Rule 2a-5 permits boards, subject to board oversight and certain other conditions, to designate certain parties to perform fair value determinations. Rule 2a-5 also defines when market quotations are "readily available" for purposes of the 1940 Act and the threshold for determining whether a fund must determine the fair value of a security. The SEC also adopted new Rule 31a-4 under the 1940 Act ("Rule 31a-4"), which provides the recordkeeping requirements associated with fair value determinations. Finally, the SEC rescinded previously issued guidance on related issues, including the role of the board in determining fair value and the accounting and auditing of fund investments. Rule 2a-5 and Rule 31a-4 became effective on March 8, 2021, and had a compliance date of September 8, 2022. While our Board of Directors has not elected to designate RGC as the valuation designee, the Company has adopted certain revisions to its valuation policies and procedures in order to comply with the applicable requirements of Rule 2a-5 and Rule 31a-4.

Table of Contents

Investment Valuation Techniques

Debt Investments: To determine the fair value of our debt investments, we compare the cost basis of the debt investment, which includes original issue discount, to the resulting fair value determined using a discounted cash flow model, unless another model is more appropriate based on the circumstances at the measurement date. The discounted cash flow approach entails analyzing the interest rate spreads for recently completed financing transactions that are similar in nature to our investments, in order to determine a comparable range of effective market interest rates for our investments. The range of interest rate spreads utilized is based on borrowers with similar credit profiles. All remaining expected cash flows of the investment are discounted using this range of interest rates to determine a range of fair values for the debt investment.

This valuation process includes, among other things, evaluating the underlying investment performance, the portfolio company’s current financial condition and ability to raise additional capital, as well as macro-economic events that may impact valuations. These events include, but are not limited to, current market yields and interest rate spreads of similar securities as of the measurement date. Significant increases or decreases in these unobservable inputs could result in a significantly higher or lower fair value measurement; however, a significantly higher or lower fair value measurement of any of the Company’s portfolio investments may occur regardless of whether there is a significant increase (decrease) in these unobservable inputs; however, a significantly higher or lower fair value measurement of any of the Company’s portfolio investments may occur regardless of whether there is a significant increase (decrease) in these unobservable inputs.

Under certain circumstances, we may use an alternative technique to value the debt investments to be acquired by us that better reflects the fair value of the investment, such as the price paid or realized in a recently completed transaction or a binding offer received in an arms-length transaction, the use of multiple probability-weighted cash flow models when the expected future cash flows contain elements of variability or estimates of proceeds that would be received in a liquidation scenario.

Warrants: Fair value of warrants is primarily determined using a Black Scholes option-pricing model. Privately held warrants and equity-related securities are valued based on an analysis of various factors including, but not limited to, the following:

•

Other adjustments, including a marketability discount on private company warrants, are estimated based on our judgment about the general industry environment. Significant increases (decreases) in this unobservable input could result in a significantly lower (higher) fair value, but a significantly higher or lower fair value measurement of any of the Company’s portfolio investments may occur regardless of whether there is a significant increase (decrease) in this unobservable input.

•

Historical portfolio experience on cancellations and exercises of warrants are utilized as the basis for determining the estimated life of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or IPOs, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input could result in a significantly higher (lower) fair value, but a significantly higher or lower fair value measurement of any of the Company’s portfolio investments may occur regardless of whether there is a significant increase (decrease) in this unobservable input.

Table of Contents

Under certain circumstances we may use an alternative technique to value warrants that better reflects the warrants’ fair values, such as an expected settlement of a warrant in the near term, a model that incorporates a put feature associated with the warrant, or the price paid or realized in a recently completed transaction or binding offer received in an arms-length transaction. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.

These valuation methodologies involve a significant degree of judgment. There is no single standard for determining the fair value of investments that do not have an active public market. Valuations of privately held investments are inherently uncertain, as they are based on estimates, and their values may fluctuate over time. The determination of fair value may differ materially from the values that would have been used if an active market for these investments existed. In some cases, the fair value of such investments is best expressed as a range of values derived utilizing different methodologies from which a fair value may then be determined.

Equity Investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. We adjust the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing subsequent to our investment. We may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. We may also reference comparable transactions and/or secondary market transactions in connection with our determination of fair value. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. These assets are recorded at fair value on a recurring basis. These valuation methodologies involve a significant degree of judgment. There is no single standard for determining the fair value of investments that do not have an active public market. Valuations of privately held investments are inherently uncertain, as they are based on estimates, and their values may fluctuate over time. The determination of fair value may differ materially from the values that would have been used if an active market for these investments existed. In some cases, the fair value of such investments is best expressed as a range of values derived utilizing different methodologies from which a fair value may then be determined.

Fair Value of Investments

The Company’s assets measured at fair value on a recurring basis subject to the requirements of ASC Topic 820 at March 31, 2023 and December 31, 2022 were as follows (in thousands):


	As of March 31, 2023
	Level 1		Level 2		Level 3		Total
Portfolio Investments
Preferred Stock	$	12,785	$	—	$	22,099	$	34,884
Common Stock		1,044		—		921		1,965
Senior Secured Term Loans		—		—		1,060,495		1,060,495
Second Lien Term Loans		—		—		13,707		13,707
Warrants		—		79		14,212		14,291
Total Portfolio Investments		13,829		79		1,111,434		1,125,342
U.S. Treasury Bill		34,974		—		—		34,974
Total Investments	$	48,803	$	79	$	1,111,434	$	1,160,316


	As of December 31, 2022
	Level 1		Level 2		Level 3		Total
Portfolio Investments
Preferred Stock	$	12,335	$	—	$	347	$	12,682
Common Stock		501		1,422		1,174		3,097
Senior Secured Term Loans		—		—		1,080,121		1,080,121
Second Lien Term Loans		—		—		13,654		13,654
Warrants		—		105		16,650		16,755
Total Portfolio Investments		12,836		1,527		1,111,946		1,126,309
U.S. Treasury Bill		—		—		—		—
Total Investments	$	12,836	$	1,527	$	1,111,946	$	1,126,309

Table of Contents

Fair Value of Financial Instruments

In accordance with ASC Topic 820 — Fair Value Measurements and Disclosures (“ASC Topic 820”), we evaluate fair value of our financial instruments. With the exception of the Company's borrowings, which are reported at cost, all assets and liabilities approximate fair value on the Statements of Assets and Liabilities due to their short maturity.

The fair value of our Credit Facility, December 2026 Notes, July 2027 Notes, August 2027 Notes, and December 2027 Notes (as defined in "Note 11 - Borrowings") is estimated using the relative market yield approach. The fair value of our Credit Facility, December 2026 Notes and August 2027 Notes are estimated using Level 3 inputs by discounting remaining payments using comparable market rates or market quotes for similar instruments at the measurement date. The fair value of our July 2027 Notes and December 2027 Notes is based on vendor pricing received, which is considered a Level 2 input, and reflects the market close price of the notes traded on the Nasdaq Global Select Market LLC under the symbol "RWAYL" and "RWAYZ", respectively.

Investment Transactions and Related Investment Income

Security transactions, if any, are recorded on a trade-date basis. We measure realized gains or losses from the repayment or sale of investments using the specific identification method. The amortized cost basis of investments represents the original cost adjusted for the accretion/amortization of discounts and premiums and upfront loan origination fees. We report changes in fair value of investments that are measured at fair value as a component of net change in unrealized appreciation (depreciation) on investments on the statement of operations.

Dividends are recorded on the applicable ex-dividend date. Interest income, if any, adjusted for amortization of market premium and accretion of market discount, is recorded on an accrual basis to the extent that we expect to collect such amounts. OID, principally representing the estimated fair value of detachable equity or warrants obtained in conjunction with our debt investments, loan origination fees, end of term payments, and market discount or premium are capitalized and accreted or amortized into interest income over the life of the respective security using the effective interest method. Loan origination fees received in connection with the closing of investments are reported as unearned income, which is included as amortized cost of the investment; the unearned income from such fees is accreted over the contractual life of the loan based on the effective interest method. Upon prepayment of a loan or debt security, any prepayment penalties, unamortized loan origination fees, end of term payments and unamortized market discounts are recorded as interest income.

Management and Incentive Fees

We accrue for base management fees and incentive fees. The accrual for incentive fees includes the recognition of incentive fees on unrealized capital gains, even though such incentive fees are neither earned nor payable to RGC until the gains are both realized and in excess of unrealized depreciation on investments. Refer to “Note 8 –Related Party Agreements and Transactions” to our financial statements in Part I, Item 1 of this Form 10‑Q for more information on the Advisory Agreement and the fee structure thereunder.

Income Taxes

We have elected to be treated, currently qualify, and intend to qualify annually as a RIC under Subchapter M of the Code. Generally, a RIC is not subject to U.S. federal income taxes on distributed income and gains if it distributes at least 90% of its net ordinary income and net short-term capital gains in excess of its net long-term capital losses, if any, to its stockholders. So long as we qualify, and maintain our status, as a RIC, we generally will not pay corporate-level U.S. federal income taxes on any ordinary income or capital gains that we distribute at least annually to our stockholders as dividends. Rather, any tax liability related to income earned by us represents obligations of our investors and will not be reflected in the financial statements of the Company. We intend to make sufficient distributions to maintain our RIC tax treatment each year and we do not anticipate paying any material U.S. federal income taxes in the future.

Table of Contents

Recent Developments

We evaluated events subsequent to March 31, 2023 through May 9, 2023.

On April 11, 2023, Mustang Bio, Inc. prepaid its outstanding principal balance of $30.0 million on the senior secured loan.

On April 13, 2023, we issued the First Supplement to the Series 2021A Senior Notes governing the issuance of $25.00 million in aggregate principal amount of its 8.54% Series 2023A Notes due April 13, 2026 ("The April 2026 Notes"). The April 2026 Notes bear an interest rate of 8.54% per year and are due on April 13, 2026, unless redeemed, purchased, or prepaid prior to such date by the Company or its affiliates in accordance with their terms. Interest on the April 2026 Notes will be due semiannually, beginning October 13, 2023.

On April 25, 2023, the Marley Spoon AG loan and security agreement was amended to: (a) extend the amortization date to January 15, 2025, (b) extend the maturity date to June 15, 2026, (c) PIK all interest through September 15, 2023, (d) add a deferral fee of €592,093 due at the maturity date; and (e) allow for a reduction in the applicable margin based on principal repayment milestones.

On April 28, 2023, we funded an investment of $2.0 million to Intellisite Holdings, Inc. (dba Epic IO Technologies, Inc).

On May 5, 2023, we funded an investment of $13.9 million to Kin Insurance, Inc.

On May 8, 2023, the investment to TRACON Pharmaceuticals, Inc. was terminated and all obligations under the contract were fully satisfied.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We commenced investment activities in portfolio securities during the quarter ended June 30, 2017 and commenced investment activities in U.S. Treasury Bills during the quarter ended December 31, 2016.

We are subject to financial market risk, including changes in the valuations of our investment portfolio. Market risk includes risks that arise from changes in interest rates, commodity prices, equity prices and other market changes that affect market sensitive instruments. The prices of securities held by us may decline in response to certain events, including those directly involving the companies we invest in; conditions affecting the general economy; overall market changes; legislative reform; local, regional, national or global political, social or economic instability; and interest rate fluctuations. Uncertainty with respect to the ongoing economic effects of the COVID‑19 pandemic has introduced significant volatility in the financial markets, and the effects of this volatility could materially impact our market risks.

Valuation Risk

Our investments may not have a readily available market price, and we value these investments at fair value as determined in good faith by our Board of Directors in accordance with our valuation policy. There is no single standard for determining fair value in good faith. As a result, determining fair value requires that judgment be applied to the specific facts and circumstances of each portfolio investment while employing a consistently applied valuation process for the types of investments we make. Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of our investments may fluctuate from period to period. Because of the inherent uncertainty of valuation, these estimated values may differ significantly from the values that would have been used had a ready market for the investments existed, and it is possible that the difference could be material.

Interest Rate Risk

We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, and cash and cash equivalents. Changes in interest rates can also affect our ability to acquire and originate loans and securities and the value of our investment portfolio. Our net investment income is affected by fluctuations in various interest rates, including SOFR and Prime rates. Increasing interest rates could have the effect of increasing our total investment income once interest rates increase above contractual interest rates floors to which our portfolio companies are subject. Conversely, we would expect the cost of our floating rate Credit Facility and unsecured notes to increase as well, offsetting the positive effect on our net interest income.

As of March 31, 2023, 100%, or $1.1 billion, of our debt portfolio investments bore interest at variable rates, consisting of approximately 68% based on SOFR and 32% based on Prime. As a policy, any interest above the cash cap, if applicable, as determined on an individual loan basis will accrue to principal and be treated as PIK interest. A hypothetical 200 basis point increase (decrease) in the interest rates on our variable-rate debt investments could increase our investment income by a maximum of $20.9 million and decrease our investment income by a maximum of $20.1 million, due to certain floors, on an annual basis.

Our debt borrowings under the Credit Facility bear interest at a floating rate, all other outstanding debt borrowings bear interest at a fixed rate. Borrowings under the Credit Facility bear interest on a per annum basis equal to the SOFR plus an applicable margin rate that ranges from 2.95% to 3.35% per annum depending on the Company's leverage ratio and number of eligible loans in the collateral pool. For additional information regarding the interest rate associated with each of our debt borrowings, refer to "Note 11 -Borrowings" to our financial statements in Part I, Item 1 of this Form 10-Q.

Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income would be dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds would increase, which could reduce our net investment income if there is not a corresponding increase in interest income generated by our investment portfolio.

We regularly measure exposure to interest rate risk. We assess interest rate risk and manage interest rate exposure on an ongoing basis by comparing our interest rate sensitive assets to our interest rate sensitive liabilities. We may hedge against interest rate and currency exchange rate fluctuations by using standard hedging instruments such as futures, options and forward contracts subject to the

Table of Contents

requirements of the 1940 Act. While hedging activities may insulate us against adverse changes in interest rates, they may also limit our ability to participate in benefits of lower interest rates with respect to our portfolio of investments with fixed interest rates.

In addition, any investments we make that are denominated in a foreign currency will be subject to risks associated with changes in currency exchange rates. These risks include the possibility of significant fluctuations in the foreign currency markets, the imposition or modification of foreign exchange controls and potential illiquidity in the secondary market. These risks will vary depending upon the currency or currencies involved, and may be exacerbated by the COVID-19 pandemic on foreign financial markets.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a‑15 under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our current disclosure controls and procedures are effective in timely alerting them to material information relating to us that is required to be disclosed by us in the reports we file or submit under the Exchange Act.

There have been no changes in our internal control over financial reporting that occurred during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

We and RGC are not currently subject to any material legal proceedings, nor, to our knowledge, is any material legal proceeding threatened against us. From time to time, we or RGC may be a party to certain legal proceedings in the ordinary course of business, including proceedings relating to the enforcement of our rights under contracts with our portfolio companies. Our business is also subject to extensive regulation, which may result in regulatory proceedings against us. While the outcome of any such legal proceedings cannot be predicted with certainty, we do not expect that any such proceedings will have a material effect upon our financial condition or results of operations.

Item 1A. Risk Factors.

You should carefully consider the risks described below and all other information contained in this quarterly report on Form 10-Q, including our interim financial statements and the related notes thereto, before making a decision to purchase our securities. The risks and uncertainties described below are not the only ones we may face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected. If that happens, you may lose all or part of your investment. Other than as set forth below, there have been no material changes known to us during the period ended March 31, 2023 to the risk factors discussed in “Risk Factors” in Part I, Item 1A of our annual report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 2, 2023.

Our business and our portfolio companies may be susceptible to economic slowdowns or recessions and to risks related to bank impairments or failures

Many of the portfolio companies in which we have invested or expect to make investments are likely to be susceptible to economic slowdowns or recessions and may be unable to repay our loans during such periods. Unfavorable economic conditions also could increase our funding costs, limit our access to the capital markets or result in a decision by lenders not to extend credit to us. These events could prevent us from increasing our investments and harm business, financial condition, operating results and prospects. In March 2023, the Federal Deposit Insurance Corporation (“FDIC”) took control of Silicon Valley Bank and Signature Bank and subsequently in May 2023 of First Republic Bank due to liquidity concerns and concerns that have arisen regarding the stability of other banks and financial institutions. Also, the impairment or failure of one or more banks with whom the Company, its portfolio companies, and/or the Adviser transact may inhibit the ability of the Company or its portfolio companies to access depository accounts. In such cases, we may be forced to delay or forgo investments, resulting in lower performance. In the event of such a failure of a banking institution where we or one or more of our portfolio companies holds depository accounts, access to such accounts could be restricted and FDIC protection may not be available for balances in excess of amounts insured by the FDIC. In such instances, we and our affected portfolio companies would not recover such excess, uninsured amounts. To the extent that we or the portfolio companies are impacted, the ability to access existing cash, cash equivalents and investments, or to access existing or enter into new banking arrangements or facilities to service our portfolio companies, may be threatened. We had no depository relationships with Silicon Valley Bank, Signature Bank, or First Republic Bank, nor did we participate in any credit facilities that were agented by or included these banks as lenders. A number of our portfolio companies had operating relationships with these banks and may have experienced operational disruptions, all of which have since been resolved.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Other than pursuant to our Dividend Reinvestment Plan, and except as previously reported by us on our current reports on Form 8‑K, we did not sell any securities during the period covered by this Form 10‑Q that were not registered under the Securities Act.

Item 3. Defaults Upon Senior Securities

None.

Table of Contents

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits

The following exhibits are filed as part of this report or hereby incorporated by reference to exhibits previously filed with the SEC:


3.1	Articles of Amendment and Restatement (1)

3.2	Articles of Amendment (2)

3.3	Second Amended and Restated Bylaws (2)

4.1	First Supplement to Note Purchase Agreement by and between the Company and the purchaser party thereto, dated April 13, 2023 (3)

31.1	Certification of Chief Executive Officer pursuant to Rule 13a‑14 of the Securities Exchange Act of 1934, as amended*

31.2	Certification of Chief Financial Officer pursuant to Rule 13a‑14 of the Securities Exchange Act of 1934, as amended*

32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

101.SCH	Inline XBRL Taxonomy Extension Schema Document

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

(1)

Previously filed as an exhibit to the Registrant’s Current Report on Form 8‑K filed with the SEC on December 19, 2016.

(2)

Previously filed as an exhibit to the Registrant’s Current Report on Form 8‑K filed with the SEC on August 19, 2021.

(3)

Previously filed as an exhibit to the Registrant’s Current Report on Form 8‑K filed with the SEC on April 14, 2023.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	RUNWAY GROWTH FINANCE CORP.
Date: May 9, 2023
	By:	/s/ R. David Spreng
		R. David Spreng
		President, Chief Executive Officer and Chairman of the Board of Directors

Date: May 9, 2023	By:	/s/ Thomas B. Raterman
		Thomas B. Raterman
		Chief Financial Officer, Treasurer and Secretary
		(Principal Financial and Accounting Officer)